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ABSTRACT 
 
JONATHAN R. HALL: The Role of Protein Degradation in 
Maintaining Genome Stability Through Regulation of Origin Licensing. 
 
(Under the directions of Dr. Jean Cook) 
 
 
 In eukaryotes cell proliferation requires the formation of a pre-replication 
complex (preRC) at chromosomal replication origins.  PreRCs are constructed from 
the origin recognition complex (ORC) which recruits Cdc6 and Cdt1, and these three 
components work together to load the minichromosome maintenance (MCM) DNA 
helicase at each origin.  Once preRC formation is completed the origin is “licensed” 
and replication of the genome can be initiated.  It is important that origin licensing 
occurs once per cell cycle during G1, and is inhibited outside of G1 and in response 
to cellular damage.  Mechanisms to restrict origin licensing rely on degradation of 
Cdc6 and Cdt1 and the Cdt1 inhibitor geminin.  Failure to properly regulate origin 
licensing leads to genome instability, contributing to the development of cancer. 
 I describe a novel mechanism for the degradation of Cdc6 in response to 
ultraviolet (UV) radiation and DNA alkylation by methyl methane sulfonate (MMS).  
This pathway is independent of previously described pathways for Cdc6 degradation 
requiring APCCdh1, and p53.  Instead, Cdc6 directly binds the HECT-family ubiquitin 
ligase Huwe1, and degradation of Cdc6 in cells treated with UV and MMS requires 
Huwe1.  My data demonstrate an important and conserved role for Huwe1 in 
regulating Cdc6 abundance after DNA damage. 
ii 
Depletion of the Cdt1 inhibitor geminin causes rereplication, a form of 
endogenous DNA damage.  I find that both Cdt1 and Cdc6 are degraded in geminin-
depleted cells.  Furthermore, I show that Cdt1 degradation in cells that have 
rereplicated requires the PCNA binding site of Cdt1 and the Cul4DDB1 ubiquitin 
ligase, and Cdc6 degradation requires the Huwe1 ubiquitin ligase.  Moreover, 
perturbations that disrupt Cdt1 and Cdc6 degradation exacerbate rereplication when 
combined with geminin depletion.   I propose that the degradation of Cdt1 and Cdc6 
in rereplicated cells represents an evolutionarily conserved mechanism that 
minimizes the extent of rereplication. 
 This dissertation researches how Cdc6 and Cdt1 are regulated in response to 
DNA damage and the consequences when these regulatory pathways are inhibited.  
The data presented in this dissertation provides insight into the mechanisms that 
prevent improper origin licensing, thus maintaining genome stability. 
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Chapter 1 
 
Introduction 
 
 
 
BIOLOGICAL SIGNIFICANCE 
The human cell has the daunting task of completely replicating over a billion 
base pairs of DNA in a limited amount of time.  The process of copying the genome 
(DNA replication) must not only be fast and efficient, but duplication of the genome 
must also be extremely accurate and occur only when the cells is prepared for DNA 
replication.  Accurate completion of DNA replication requires that the entire genome 
is completely copied only once, and is duplicated free of errors and deletions.  
Furthermore, the copied genome must be precisely segregated into two new cells.  
Completion of this task is a scientific marvel, and is required for the successful 
transfer of genetic material and maintenance of genome stability.   
Normally, cells can completely replicate the genome without any difficulty; 
however cancer cells display several characteristics of defects in DNA.  First, many 
cancers arise from gene mutations that affect expression of proteins required to 
regulate cell proliferation.  Mutations in the genome can result in a specific protein 
being expressed in an inactive form, expressed at the wrong time, or not expressed 
at all.  Improper expression of genes can affect how cell cycle regulatory pathways 
are activated and inhibited, and contribute to uncontrolled cell proliferation, a second 
characteristic of cancer.  In addition, failure to copy the genome completely and only 
once can result in the deletion of genetic material, thereby promoting genome 
instability.  The inability to maintain genome stability is a contributing factor to 
tumorigenesis, and many of the factors that contribute to tumorigenesis are poorly 
understood.  Through understanding how DNA replication is regulated in normal 
cells, we can gain insight into how disruptions in these regulatory pathways can lead 
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to the development of cancer.  This dissertation will explore the mechanisms by 
which DNA replication is regulated to maintain genome stability 
 
THE EUKARYOTIC CELL CYCLE 
When cell proliferation is discussed reference is often made to the four 
phases of the cell growth cycle (Figure 1.1).  The G1 (Gap 1) phase of the cell cycle 
is considered the first stage of the cell cycle and it is during this phase in which the 
cell prepares for DNA replication including expression of many components required 
to initiate DNA replication.  S phase is when the cell completely replicates the entire 
genome.  The completion of S phase gives rise to the second gap phase, G2, in 
which a cell prepares for mitosis (M phase).  During mitosis, the replicated DNA is 
segregated into separate nuclei, followed by cellular division resulting into two new 
daughter cells (reviewed in[1]).   
 
ORIGIN LICENSING 
To complete the extraordinary task of duplicating the genome, cells initiate 
replication at thousands of sites throughout the genome.  Initiation of DNA 
replication is the first committed step towards cell proliferation and requires the 
formation of a multi-protein complex, termed the prereplication complex (preRC) at 
sites of replication called origins.  Construction of the preRC requires four 
components consisting of the six subunit origin recognition complex (ORC), the six 
subunit minichromosome maintenance (MCM) complex, Cdt1 (Cdc10 dependent 
transcript 1), and Cdc6 (Cell division cycle 6)  
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Formation of the preRC at the site of replication origins, termed “origin 
licensing”, occurs late in mitosis and early in G1.  The binding of ORC (Orc1-6) to 
DNA is the first step towards preRC formation (Figure 1.2).  Once ORC is bound to 
DNA its associates with the replication proteins Cdc6 and Cdt1.  Cdc6 and Cdt1 bind 
to ORC separately; however the binding of both Cdc6 and Cdt1 to origins is required 
for the loading of the MCM complex onto DNA (reviewed in [2]and [3], Figure 1.2).   
 
The origin recognition complex (ORC) 
The origin recognition complex was identified in yeast for proteins binding to 
autonomously replicating sequence (ARS) consensus sequence (ACS).  ARS 
sequences have been shown to act as true origins of replication in the budding yeast 
chromosome.  Within ARS elements is the conserved ACS sequence, consisting of 
11 DNA base pairs that are required for ORC binding [4]. ORC is comprised of six 
subunits (Orc1-6), which are evolutionarily conserved.  However, the sequence 
dependent DNA binding of ORC is lost in most eukaryotes, likely due to the lack of a 
consensus origin sequence in organisms outside of budding yeast.  Additionally, 
ORC from fission yeast, frog, and human prefer A-T rich DNA consequences [5].  
The lack of sequence specificity in ORC DNA binding is confirmed by the fact that 
human ORC can replace frog ORC in replication assays [5, 6].   
ORC binds to DNA at replication origins, and serves as a docking pad for the 
binding of Cdc6 at Cdt1.  ORC is a member of the family of AAA+ (ATPases 
Associated with various cellular Activities) ATPases, with only Orc3 lacking ATPase 
activity (reviewed in [3]).  In vitro studies have shown that only ORC in the ATP 
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bound state can bind to DNA, but hydrolysis of ATP by ORC is not required for ORC 
binding to DNA [4, 7, 8].  The ATP binding by ORC is required for the ORC-Cdc6 
interaction on DNA, with ORC mutants defective in ATP binding failing to recruit 
Cdc6 [9-11].   In addition, ATP hydrolysis by ORC is required for the loading of the 
MCM complex onto DNA [12].  Further discussion on the role of ORC in the loading 
of the MCM complex onto DNA will be discussed later.   
Interestingly, ORC ATPase activity is inhibited by single-stranded (ss) and 
double-stranded (ds) DNA [4].  In addition, Cdc6 can bind to ORC in vitro and 
influence ORC’s sensitivity to proteases, suggesting Cdc6 binding induces a 
conformational change of DNA bound ORC, and activates ORC ATPase activity [11, 
13, 14].  
 
Cdc6 
Cdc6 was discovered in the original screen for budding yeast mutants with 
defects in the cell division cycle (cell division cell cycle protein 6; [15]).  The role of 
Cdc6 (Cdc18 in fission yeast) in DNA replication was first shown in budding yeast, 
as a protein required to initiate DNA replication and complete S phase.  This study 
showed that mutations to Cdc6 results in defects in initiation of DNA replication [15].  
Additional studies have confirmed that in the absence of Cdc6, cells fail to initiate 
DNA replication and arrest in S phase [16, 17].  Furthermore, de novo synthesis of 
Cdc6 is required during G1 for replication initiation [18, 19]The replication defects 
attributed to the Cdc6 mutants can be explained by the essential role of Cdc6 in 
preRC assembly, a requirement for replication initiation [20].  Following the binding 
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of ORC to replication origins, Cdc6 is recruited to ORC.  The interaction between 
Cdc6 and ORC was originally confirmed in budding yeast through 2D gel analysis 
and other biochemical assays [21].  Cdc6 works in conjunction with Cdt1 to load the 
MCM complex onto DNA, and Cdc6 interacts with Cdt1 through its N-terminal non-
catalytic domain [22].  Immunodepletion of Cdc6 frog extracts inhibits the initiation of 
DNA replication by interfering with MCM loading [23, 24] 
Cdc6 is member of the family of AAA+ ATPases, and has strong amino acid 
sequence similarity to Orc1 [25, 26].  In addition, recombinant human Cdc6 has 
been shown to bind and hydrolyze ATP in vitro [27].  The role of Cdc6 in preRC 
assembly is dependent on its ability to bind and hydrolyze ATP.  However, ATP 
binding and ATP hydrolysis have distinct roles in the functions of Cdc6, and both are 
required for Cdc6 function.  One proposed model is that Cdc6 binds ATP after Cdc6 
is bound to ORC [28].  Cdc6 mutants that cannot bind ATP are defective in S phase 
entry [29, 30], suggesting that ATP bound Cdc6 is required for preRC assembly 
through recruitment of Cdt1 and the MCM complex.  Cdc6 can associate with Cdt1 
and the MCM complex independent of ATP hydrolysis; however the ATPase activity 
of Cdc6 is required for the fixed loading of the MCM complex at replication origins.  
Cdc6 mutants impaired in their ability to hydrolyze ATP display defects in entry into 
S phase and fail to initiate replication [22, 28, 31-33].  
Structural studies using an archaeal bacterial homolog of Cdc6 has provided 
information on the function of Cdc6.  The Probaculum aerophilum homolog of Cdc6 
folds into a three domain structure.  Domain I and II consist of the ATP binding and 
hydrolysis domains [30] and are required for MCM loading [31, 32].  Domain III 
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consists of a bundle of α helices, including a winged-helix (WH) fold that suggests a 
DNA binding motif, and mutations to the WH domain in Cdc6 from fission yeast 
results in loss of DNA replication [30]. However, there has been no direct evidence 
that Cdc6 binds DNA directly.  The dual lobe formed by domains I and II are similar 
to other DNA sliding clamp loading proteins [30].  Replication factor C (RFC), a 
AAA+ ATPase that acts a clamp loader in the loading of the DNA polymerase 
processitivity factor PCNA, shares structurally confirmed similarity to Cdc6 [31].  In 
addition, Cdc6 contains significant sequence similarity to subunits of eukaryotic and 
prokaryotic clamp loader proteins, such as the dnaC helicase loader, and suggests 
that Cdc6 may also function as a nucleotide-dependent DNA sliding clamp loader 
[30-32]. 
 
 
Cdt1 
Cdt1 was originally isolated from fission yeast as a gene that was regulated 
by the Cdc10 transcription factor (Cdc10 dependent transcript 1) [34].  In this screen, 
cells carrying a null allele of Cdt1 were defective in DNA replication, suggesting an 
essential role for Cdt1 in DNA replication [34].  The divergence of Cdt1 sequence 
delayed the discovery of Cdt1 homologs in other eukaryotes, but Cdt1 is 
evolutionarily conserved [35]. 
Similar to the recruitment of Cdc6 by ORC; Cdt1 is also recruited to origins by 
binding to ORC.  Cdt1 has also been shown to be required for the recruitment of the 
MCM complex to chromatin.  In fission yeast the absence of Cdt1 blocks the 
initiation of DNA replication by inhibiting the association of Mcm4 with chromatin 
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[36].  This observation was confirmed; when budding yeast Cdt1 mutants fail to 
assemble the MCM complex and initiate S phase [35].  However, in both of these 
studies the depletion of Cdt1 abolished the binding of the MCM complex to DNA, but 
the depletion of Cdt1 had no effect on ORC or Cdc6 association with origins [35, 36].  
Cdt1 is required for the loading of the MCM complex, however Cdt1 has no 
described enzymatic activity, and it has been proposed that Cdt1 may act as an 
escort by binding to the MCM complex and bringing the helicase to the origin [28].  
The quantification of Cdt1 and MCM association with ORC revealed that these two 
proteins associated with ORC at similar levels and at an equal molar ratio [28].  This 
result suggests that in budding yeast that Cdt1 and the MCM complex are loaded 
together onto the Cdc6-ORC-origin complex [28].   
 
The minichromosome maintenance (MCM) complex 
The MCM complex is comprised of six subunits (Mcm2-7) and is conserved in 
all eukaryotes.  The MCM complex was originally discovered in a budding yeast 
genetic screen for mutants that were defective for the maintenance of 
minichromosomes [37, 38].  The rationale was that mutations that reduce the activity 
of proteins necessary for DNA replication would have more dramatic effects on 
minichromosomes, which have only one origin, are non-essential, and can be lost 
from cells.  
Structural studies using electron microscopy from fission yeast describe the 
MCM complex is a heterohexameric ring with each subunit existing in 1:1:1:1:1:1 
stoichiometric ratio [39].  In addition, electron microscopy studies from the archaeal 
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bacterium, Methanobacterium thermoautotrophicum, has shown that the MCM 
complex exists as a dodecamer formed by two opposed ring-liked hexamers [40].  
The crystal structure of the N-terminal domain of the Methanobacterium 
thermoautotrophicum MCM complex confirmed the dodecamer structure was the 
shape of a dumbbell and a channel large enough to include single-stranded (ss) and 
double-stranded (ds) DNA [41].  The crystal structure suggests that the MCM 
complex wraps around the DNA, with the DNA threaded through the center. 
Yeast degron studies of the MCM complex revealed that all MCM mutants 
displayed elongation defects and stopped replication immediately, following subunit 
degradation at the restrictive temperature [42].  These effects are very similar to the 
studies done with the E.coli dnaB helicase which display the similar defectives in 
elongation [43].  Like ORC and Cdc6, the MCM complex is an ATPase.  The MCM 
complex is required for replication initiation and elongation in all eukaryotes, 
suggesting the MCM complex is the replication helicase required for unwinding the 
DNA during DNA replication.  Mcm4/6/7 sub-complexes purified from human cells 
display ATPase activity, the ability to bind both ssDNA and dsDNA, and weak 
helicase activity [44, 45].  In addition, these studies have been confirmed in yeast, 
frog and mouse [46-49]. 
Interestingly, studies in eukaryotes including human, budding yeast, and 
frogs, have demonstrated that the number of MCM complexes loaded onto DNA 
greatly exceeds the number of replication origins that fire during S phase [50-55].  In 
addition, S phase is still completed when the number of MCM complexes is reduced 
to 1-2 per origin [52, 55-57].  This observation, described as the “MCM paradox”, 
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raises the question of the role of these excess MCM complexes.  Further insight into 
the “MCM paradox” has come from studies in Xenopus and human cells.  These 
studies have shown that the excess MCM complexes license “dormant” origins that 
are not required for completion of an unperturbed S phase, and dormant origins 
typically do not fire during S phase.  However, dormant origins are activated within 
active replicating regions if replication fork progression is inhibited, by chemical 
treatments that inhibit a DNA polymerase (aphidicolin) or reduce pools of dNTPs 
(hydroxyurea, HU).  Interestingly, replication at dormant origins is initiated despite 
the activation of S-phase checkpoints [58, 59].  Cells with lower MCM levels still 
replicate at normal rates, but when challenged with replication inhibitors HU and 
aphidicolin these cells had reduced rates of DNA synthesis and cell viability.  Partial 
knockdown of MCM expression induces hypersensitivity to otherwise nontoxic levels 
of HU [58, 59].  These studies suggest a mechanism that cells utilize to continue 
DNA replication under conditions of replication stress. 
The MCM complex is efficiently loaded onto the DNA through the sequential 
ATPase activities of both Cdc6 and ORC.  The ATPase activity of Cdc6 precedes 
ATP hydrolysis by ORC, and is required for the initial loading of a MCM complex 
onto DNA [28].  Mutations to the catalytic domain of Cdc6 that inhibit ATP hydrolysis, 
also prevent the DNA loading of the MCM complex. [28, 31, 60].   However, it is the 
ATPase activity of ORC that is required for the loading of additional MCM complexes 
[28].  Models suggest that ORC and Cdc6 may function as sliding clamp loaders, 
opening the MCM ring, and depositing the helicase onto the DNA [11, 28, 61].   The 
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mechanism of how the MCM complex is loaded onto DNA has not been completely 
defined and is an ongoing question in the field.  
 
INITIATION OF DNA REPLICATION  
Following the loading of the MCM complex onto DNA, preRC formation is 
complete and the origin is licensed for replication.  In addition, once the MCM 
complex has been loaded onto DNA, ORC, Cdc6, and Cdt1 are no longer required 
for replication and to maintain the MCMs on DNA [24, 36, 53, 62].  Studies in 
Xenopus and budding yeast have shown that after the loading of the MCM complex 
onto DNA, replication is still initiated and the MCMs remain DNA bound even if ORC 
or Cdc6 have been depleted from extracts or removed from DNA with high salt [24, 
36, 51, 53, 62].  Furthermore, fission yeast can still complete S phase, when Cdt1 
expression is lost in early S phase arrested cells (arrest with hydroxyurea) [36].  
Therefore, once the origin has been licensing the activities of ORC, Cdc6 and Cdt1 
are not required to initiate and complete DNA replication.   
Initiation of DNA replication requires the activities of two conserved protein 
kinases that are required for helicase activation and the loading of the replication 
machinery.  Before transitioning into S phase, the cyclin-dependent kinase Cdk2, 
and the Dbf4-dependent kinase (Ddk) Cdc7 become active.  Both kinases are 
inactive in their monomeric form, and are activated by the binding of an activating 
subunit, cyclin (for Cdks), and Dbf4/Drf1 (for Ddks).  The activities of Cdk2 and Cdc7 
are required for the transition to DNA replication, through recruitment of factors 
required for helicase activation, recruitment of the replication machinery, and 
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initiation of replication, such as Cdc45, the GINS complex, and DNA polymerase α 
(reviewed in [2, 3].   
It has been shown in many organisms, including humans, that Cdc7 directly 
phosphorylates Mcm2, Mcm4, and Mcm6 [63-69].  The Cdc7-dependent 
phosphorylation of the MCM complex induces a conformational change and 
promotes loading of the replication machinery [70, 71].  Cdc45 binds to the 
phosphorylated MCM complex, travels with the replication fork, and is required for 
DNA elongation [72, 73].  Furthermore, Cdc45 is required to load the replication 
machinery, and activate the MCM helicase [70, 74].  Studies in Xenopus showed 
that isolated MCM complexes displayed helicase activity, only if bound by Cdc45 
[49]  
 
ORIGINS NEED TO BE LICENSINED ONCE DURING THE CELL CYCLE 
 It is critical that origins are only licensed once per cell cycle.  Failure to 
correctly control origin licensing can lead to improper preRC assembly at previously 
fired origins.  The re-initiation of replication at origins that have already fired results 
in rereplication of regions of the genome (Figure 1.3).  The presence of even a small 
amount of rereplicated DNA can have catastrophic consequences leading to 
changes in centrosome number, DNA insertions, DNA rearrangements and other 
characteristics of genome instability [75-80].  It has been shown experimentally that 
overexpression of Cdc6 and Cdt1 is sufficient to induce rereplication in human cells; 
resulting in double-strand DNA breaks (DSBs) and activation of a DNA damage 
response.   
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Furthermore, the expression of Cdc6 and Cdt1 are often elevated in tumors 
and in tumor-derived cell lines, suggesting elevated expression of Cdc6 and Cdt1 
may contribute to tumorigenesis [81-84].  Additional studies have shown that mouse 
embryonic fibroblasts overexpressing Cdt1 formed tumors when injected into 
immune-compromised mice [82].  Mice overexpressing Cdt1 in T-cells develop 
lymphomas when the p53 tumor suppressor is deleted (these cells develop 
lymphomas at a higher frequency than in the p53 null mice) [85].  Taken together, 
these studies reinforce the need to restrict origin licensing to once per cell cycle and 
that proper regulation of preRC assembly is required to maintain genome stability.    
 
REGULATION OF PreRC ASSEMBLY 
One way in which human cells prevent origin re-licensing is through 
regulation of the preRC components.  During the cell cycle the activity, expression, 
degradation, and localization of preRC components are regulated to ensure preRC 
formation does not occur outside of G1, although the mechanisms for many of these 
events have yet to be characterized completely [77, 86-90].  Many of the 
mechanisms that regulate preRC assembly, are themselves regulated in the cell 
cycle, therefore multiple mechanisms are in play to regulate a given preRC 
component, and to ensure that preRC assembly is prohibited outside of G1.  
Additionally, the presences of multiple mechanisms to inhibit preRC assembly 
suggest that a single mechanism is unable to properly restrict preRC formation.  As 
mentioned above, elevated expression of Cdc6 and Cdt1 are commonly found in 
tumor cell lines, and several pathways that regulate preRC assembly are found to be 
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deregulated in several cancers (such as the E2F/Rb pathway [91]; and cyclins and 
cyclin-dependent kinases [92]). 
 
Regulation of preRC components by the E2F transcription factor 
One method by which preRC assembly is inhibited is through the regulation of 
the expression of preRC components.  The expression of the preRC components is 
regulated by the E2F family of DNA-binding transcription factors (Figure 1.4A) [93-
96].  The E2F transcription factor is regulated by the retinoblastoma tumor 
suppressor protein (Rb).  The inhibition by Rb of E2F-mediate gene transcription can 
occur through at least three distinct mechanisms when Rb is recruited to the E2F-
regulated gene promoters.  First, the Rb protein binds to the activation domain of 
E2F; repressing transcription of E2F controlled genes [97, 98].  Second, the 
recruitment of Rb to gene promoters blocks the assembly of transcription initiation 
complexes, possibly inhibiting the activity of adjacent transcription factors [99].  
Third, Rb interacts with complexes that modify chromatin structure, serving as a 
bridge allowing chromatin modifying enzymes to interact with E2F-regulated 
promoters, thereby repressing gene transcription [100-103]. 
During the G1 phase of the cell cycle, cyclin D/Cdk4/6 and cyclin E/Cdk2 
become active and phosphorylate Rb.  The phosphorylation of Rb results in the 
disassociation of Rb from E2F, enabling transcription of genes required for DNA 
replication [104-106].  Therefore, expression of the preRC components and other 
regulators of cell cycle progression are controlled by the E2F-Rb pathway (Figure 
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1.4A), and this mechanism restricts the expression of preRC components to times 
suitable for origin licensing. 
 
Cyclin-dependent kinase (Cdk) inhibition of preRC assembly 
 Cdks plays a complex role in regulation of DNA replication.  First, Cdk activity 
activates origins for replication as cells transition into S phase.  Second, the same 
Cdk activity is required to prevent origin licensing until the subsequent G1 phase [86, 
87, 89, 90].  One mechanism by which Cdks prevent rereplication is through 
inhibition of preRC assembly (Figure 1.4B).   
All eukaryotes rely heavily on Cdk activity to prevent rereplication.   The first 
studies to show Cdks prevent rereplication in any eukaryote were performed in 
budding yeast.  These studies showed that depletion of the mitotic cyclin or mitotic 
Cdk results in rereplication [107, 108].  Furthermore, inactivation of Cdk activity in 
G2/M results in yeast results in full rereplication of the genome [109, 110].  The link 
between inhibition of preRC assembly and Cdk activity is further supported by 
results in budding yeast which indicate that elevated expression of Cdk activity in G1 
prevents new preRC formation [19, 109].  Xenopus cell free in vitro replication 
studies showed that when cyclin E or cyclin A- Cdk2 concentrations are increased in 
the egg cytosol before the addition of sperm chromatin, the chromatin fails to initiate 
replication [111].  This result demonstrates that Cdk2-cyclin A or E could negatively 
regulate DNA replication.  Furthermore, the elevated Cdk2 activity prevents the 
loading of Mcm3 [111].  Evidence that Cdks inhibit rereplication in human cells come 
from studies using a mammalian cell line in which expression of the endogenous 
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CDC2 (Cdk1) gene is regulated by an inducible promoter [112].  In the absence of 
Cdc2 expression cells underwent extensive DNA rereplication, indicating Cdc2 is 
required for prevention of rereplication [112].  Fluctuations of cyclin E levels are 
required to drive endoreduplication cycles in Drosophila [113].  Although the 
components of the preRC are conserved, the effects of Cdk activity on the preRC 
components vary among organisms [86, 89, 90, 114].  In addition, the roles by which 
Cdks inhibit origin licensing in metazoans in unclear.   
The Cdk2 phosphorylation of the MCM complex may inhibit the ability of the 
MCM complex to bind ORC, Cdc6, or Cdt1  [86, 87, 89, 90, 114], while the role of 
Cdks in the regulation of ORC is controversial.  It has been reported that the Orc1 
subunit is targeted for degradation through an SCF-dependent mechanism that may 
depend on Cdk activity [115-117], however in some cell lines Orc1 is phosphorylated 
in S phase but remains stable throughout the cell cycle [118, 119].  In addition, Cdk 
activates Cdt1 and Cdc6 (only in yeast) for degradation, inhibits Cdc6 degradation in 
humans, and Cdk activity is required for the regulation of the ubiquitin ligases that 
regulate the activity of Cdc6 and Cdt1 either directly or indirectly [120-126].  The 
regulation of Cdt1 and Cdc6 by Cdks will be highlighted later in this chapter when 
discussing the cell cycle regulation of Cdt1 and Cdc6. 
 
Ubiquitin-mediated protein degradation 
Another method by which new preRC construction is inhibited after origin 
licensing is through the degradation of the Cdc6 and Cdt1 (Figure 1.4C).  
Ubiquitination is an enzymatic pathway that requires three families of enzymes (E1, 
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E2, and E3) which results in the transfer of the small protein ubiquitin to a target 
protein.  The construction of chains of ubiquitin on a target protein (called poly-
ubiquitination) marks that protein for degradation through proteolysis by the 26S 
proteasome (reviewed in [127, 128]).  The E3 ubiquitin ligase is the enzyme that 
catalyzes the poly-ubiquitination of a target protein, and the activity of E3 ubiquitin 
ligases play a critical role in regulating origin licensing.  The anaphase promoting 
complex (APC), SCFSkp2 and Cul4DDB1 ubiquitin ligases will be discussed throughout 
this dissertation and are members of the RING (really interesting new gene) family 
ubiquitin ligases.  RING family E3s commonly exist as large multi-subunit 
complexes, and act as a scaffold bringing together the E2 and the target protein 
(Figure 1.5).  SCF (Skp1 – Cullin – F-box protein) and SCF-like complexes are the 
largest class of ubiquitin ligases.  Cullins are a closely related family of 6 proteins 
that bind a ring finger protein, which bind and activate E2 conjugating enzymes.  The 
Skp protein serves as an adaptor (Skp1 or DDB1), bridging the cullin (Cul1 or Cul4) 
with the F-box substrate binding protein (Skp2 or Cdt2) (Figure 1.5).  Unlike other 
classes of ubiquitin ligases, RING E3s catalyze the transfer of ubiquitin from the E2 
directly to the target protein with no E3-ubiquitin intermediate (Figure 1.5) [127, 128].  
The other class of ubiquitin ligases, the HECT family of ubiquitin ligases will be 
discussed in Chapter 2 regarding the regulation of Cdc6. 
 
Cell cycle regulation of Cdc6 
Cdc6 is a substrate of Cdk2, and the N-terminus of Cdc6 contains three Cdk 
phosphorylation sites.  Unlike the regulation in yeast where Cdk phosphorylation of 
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Cdc6 is a signal for protein degradation [121-123], metazoan Cdc6 is not inhibited by 
Cdk activity, and Cdc6 remains bound to chromatin after origin licensing until mitosis 
[119, 129].  Furthermore, overexpression of cyclin A in human cells does not affect 
Cdc6 nuclear localization, and Cdc6 phosphorylated on serine-54 maintains a high 
affinity for chromatin during S phase [130].  Evidence suggests that excess Cdc6 
that is not contained within preRCs is exported out of the nucleus during S phase 
through a mechanism dependent on Cdk activity, although there is little evidence to 
suggest this mechanism inhibits the re-licensing of origins [131, 132].  Therefore, in 
human cells it appears that unlike other components of the preRC the activity of 
Cdks does not inhibit Cdc6 function, and suggests that Cdc6 is regulated through a 
mechanism independent of Cdk activity. 
The main mechanism for Cdc6 regulation during the cell cycle is by ubiquitin-
mediated protein degradation catalyzed by the anaphase promoting complex (APC).  
APC is a large 13 subunit E3 ubiquitin ligase complex that exists in two forms: the 
mitotic form, APCCdc20, requiring the substrate targeting protein Cdc20; and the non-
mitotic form, APCCdh1, containing the Cdc20 homolog Cdh1.  Cdk phosphorylation of 
the APC activator, Cdh1, inactivates APC late in G1 until metaphase and APC is 
also inhibited by the mitotic spindle checkpoint [133, 134].  Therefore APC is only 
active from late in mitosis, when the cyclins have been degraded and the spindle 
checkpoint inhibition has been removed, until Cdk activity increases as cells prepare 
to enter S phase.  
During mitosis and G1, Cdc6 is ubiquitinated by APCCdh1 (Figure 1.7) [126, 
135]. Cdc6 contains a Destruction Box (D-Box) in the N-terminus of the protein 
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(residues 56-64).  The D-box is a sequence that is commonly found in APC 
substrates and is required for substrate ubiquitination [136].  Deletion of D-box 
residues 58-61 is sufficient to stabilize Cdc6 during the cell cycle [135].  In addition, 
Cdc6 also contains a KEN motif (consisting of the amino acid residues K-E-N) that 
has been described as a Cdh1-targeting motif distinct from the D-box [137].  
Mutations to the KEN motif partial stabilized Cdc6, suggesting that both motifs are 
required for the APC-mediated degradation [135].   
Interestingly, the degradation of Cdc6 is inhibited when Cdc6 is 
phosphorylated by cyclin E/Cdk2 [126, 138].  Mutation of all three Cdk 
phosphorylation sites on Cdc6 from serine to aspartic acid (mimics the 
phosphorylated state, Cdc6DDD) stabilizes Cdc6 in the presence of exogenous 
cyclin E [126].  However, when the Cdk sites are altered from serine to alanine 
(mimics the unphosphorylated state, Cdc6AAA), Cdc6 is efficiently degraded in the 
presences of exogenous cyclin E.   The N-terminal Cdk phosphorylation sites of 
Cdc6 reside within the D-box and KEN motifs, and APCCdh1 recognition of Cdc6 is 
diminished by the phosphorylation of Cdc6.   Both the wild-type Cdc6 and the Cdc6 
unphosphorylated mutant (Cdc6AAA) could interact with Cdh1, as measure by co-
immunoprecipitation [126].  However, the association between Cdh1 and Cdc6 was 
lost in the phosphorylated mimic mutant (Cdc6DDD).  The Cdk-mediated 
phosphorylation of Cdc6 occurs presumably to ensure timely preRC formation at 
origins during G1 [126, 138].   
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Cell cycle regulation of Cdt1 
Following origin licensing Cdt1 activity is inhibited through interaction with the 
geminin protein (Figure 1.6) [22, 139-142].  Geminin was discovered in Xenopus 
extract during a screen for substrates of the anaphase promoting complex (APC), 
and is an inhibitor of DNA replication [120].  In addition, a second geminin cDNA was 
found that has an alternative role in determination of neural cell fate during 
embryonic development [143].  Furthermore, the mechanism of DNA replication 
inhibition by geminin is only present in metazoans [120].  Geminin is targeted for 
degradation as cells transition into anaphase and G1 by APC, and therefore is only 
present in the cell during S, G2, and early mitosis [120].  
Geminin inhibits DNA replication by binding to Cdt1 on chromatin, and this 
interaction blocks preRC formation at previously licensed origins [120, 141, 144, 
145].  Geminin inhibits Cdt1 function by blocking Cdt1 binding to both Cdc6 and 
Mcm2 [22].  However, the geminin protein is only present during S phase and G2 
due to ubiquitination by the APC E3 ubiquitin ligase ([120] and APC regulation 
described above).  The high expression of Cdt1 and low expression of geminin 
during G1, results in a small window of time during the cell cycle in which Cdt1 can 
participate in origin licensing.  Loss of geminin in human and drosophila cells 
induces rereplication, due to the dysregulation of Cdt1.  
In addition to the physical inhibition of Cdt1 by geminin, Cdt1 is targeted for 
ubiquitin-mediated protein degradation [124, 125, 146-150].  As cells transition from 
G1 to S phase, Cdt1 is phosphorylated by Cdk2 on residue threonine-29.  
Furthermore, the phosphorylation of T29 is recognized by the F-box protein Skp2, a 
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component of the SCFSkp2 ubiquitin ligase (Figure 1.6).  The ubiquitination of Cdt1 by 
the SCFSkp2 is dependent on Cdt1 phosphorylation on residue T29, and requires the 
cyclin binding motif in the N-terminus of Cdt1 [124, 125].  The ubiquitin mediated 
regulation of Cdt1 by SCFSkp2 is limited to S and G2 phases of the cell cycle due to 
the activity of Cdk2, and the degradation of Skp2 by APC outside of S and G2[151] . 
However, inhibition of Cdk2 activity does not completely stabilize Cdt1 during 
S phase. Deletion of the cyclin binding (Cy) motif or mutation of T29 to alanine (to 
mimic the unphosphorylated state) does not stabilize Cdt1 during S phase [147].  In 
addition, it was also observed that Cdt1 does not accumulate in Skp2-/- mouse 
embryonic fibroblasts (MEFs; [152]).  These observations suggest that Cdt1 stability 
during S phase may be controlled by more than one mechanism.  A study in 
Caenorhabditis elegans showed that worms lacking Cul4 fail to degrade Cdt1 during 
S phase [153].  In fact, Cdt1 is degraded in Xenopus through a replication-
dependent mechanism requiring the Cul4DDB1 E3 ubiquitin ligase [150].  The 
ubiquitination of Cdt1 by Cul4DDB1 requires an interaction between Cdt1 and the 
proliferating cell nuclear antigen (PCNA, Figure 1.6) [150, 154-156].  PCNA is a 
homotrimeric ring protein that clamps around the DNA, and serves as a processivity 
factor for DNA polymerases and is involved in DNA repair [157, 158].  Cdt1 binds to 
PCNA through a highly conserved consensus PCNA interacting protein (PIP) motif 
that resides in the first 10 N-terminal residues.   Further studies in human cells have 
shown that Cdt1 is still degraded during S phase when the cyclin interacting (Cy) 
motif is deleted, however when the Cy motif and the Cdt1 PIP motif have been 
deleted Cdt1 is stable during S phase [155].  Therefore, in human cells degradation 
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of Cdt1 relies on two overlapping mechanisms, requiring the SCFSkp2 and the 
Cul4DDB1 ubiquitin ligases [148]. 
Evidence in Xenopus demonstrates only chromatin bound Cdt1 is 
ubiquitinated by Cul4DDB1, and suggests the interaction between PCNA and Cdt1 
may recruit Cdt1 to chromatin for ubiquitination by the Cul4DDB1 ubiquitin ligase [150, 
154].  However, the requirement of Cdt1 chromatin association for ubiquitination has 
not been confirmed in a human model system.   
In addition, studies in Caenorhabditis elegans and human cells have shown 
that cells lacking Cul4DDB1, re-initiate DNA replication resulting in accumulation of 
double strand DNA breaks and other markers of genome instability [76, 153].  In 
Xenopus, loss of the Cdt1-PCNA interaction induces rereplication [154].   
Furthermore, overexpression of Cdt1 is sufficient to induce rereplication in human 
cells [75].  These studies suggest that the activity of Cul4DDB1 is critical to maintain 
the integrity of the genome. 
Through the various overlapping mechanisms for regulating origin licensing 
described above, the cell creates a small window during the cell cycle in which origin 
licensing can occur.  These mechanisms for restricting preRC assembly require Cdk 
activity and the inhibition of Cdc6 and Cdt1.  As cells exit mitosis ORC is bound to 
replication origins.  It is during this time that APC activity keeps Cdc6, cyclin A, and 
geminin levels low.  As cells progress through G1, Cdk levels rise and phosphorylate 
and stabilize Cdc6.  Phosphorylated Cdc6 and Cdt1 (free from geminin) can bind 
ORC, and load the MCM complex.  Finally, origin licensing is complete before Cdk2 
become high at the G1/S transition.  As cells enter S phase Cdt1 is bound by 
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geminin, phosphorylated and degraded, thereby preventing origin licensing until next 
cell cycle.    
 
REGULATION OF ORIGING LICENISNG IN RESPONSE TO DNA DAMAGE 
DNA damage inactivates Cdks  
It has already been described that eukaryotes rely heavily upon Cdk activity 
to restrict origin licensing outside of G1, and inhibition of Cdk activity can result in 
the reloading of the MCM complex and origin re-licensing.  However, in response to 
DNA damage Cdks become inactivated as part of a DNA damage response to stop 
cell proliferation, and to allow time to repair damage DNA [158, 159].  
The detection of DNA damage activates a canonical DNA damage pathway 
requiring the ATM and ATR DNA damage kinases (Figure 1.8).  Ataxia-
telangiectasia mutated (ATM) and ATM and Rad3 related (ATR) proteins activate a 
signaling pathway that ultimately inhibits cell cycle progression [159].  In response to 
DNA damage ATR and ATM are activated, resulting in the activating 
phosphorylation of the ATR and ATM effectors checkpoint kinase 1 (Chk1) and 
checkpoint kinase 2 (Chk2).  The activities of Chk1 and Chk2 are required to 
activate downstream effectors leading to the inhibition of Cdk activity (Figure 
1.8)[159] .  In response to DNA damage the expression and stability of the p53 
tumor suppressor protein is regulated through phosphorylation at several sites, in 
part by the ATR, ATM, Chk1 and Chk2 kinases [159, 160].  The stabilization of p53 
induces expression of the Cdk inhibitor p21, which mediates a cell cycle arrest 
(Figure 1.8).  Activation of the Chk1 and Chk2 kinases also inhibits the activity of the 
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Cdc25 phosphatases (Cdc25A, Cdc25B, and Cdc25C); a family of phosphatases 
that are required to remove an inhibitory phosphate from Cdks and activate Cdks 
(Figure 1.8) [161].  The ATM-Chk2 pathway is typically activated in response to 
formation of DNA double strand breaks.  The ATR-Chk1 pathway is activated by 
other forms of DNA damage such as ultraviolet radiation and DNA modifying agents 
which result in DNA lesions and adducts which stall replication forks, a form of 
replication stress [158, 160, 161].   
The inhibition of Cdk activity in response to DNA damage outside of G1/S 
removes one of the key defenses to restrict origin licensing to G1, and creates an 
environment favorable to re-license fired origins because of low Cdk activity (Figure 
1.9).  Inhibition of Cdk activity in G2 induces inappropriate MCM chromatin loading, 
and if Cdk activity is restored these reloaded MCM complexes are sufficient to 
promote rereplication [107, 162, 163].  If genome stability is to be maintained, then 
Cdc6 and Cdt1 must be inhibited to prevent preRC formation (MCM chromatin 
loading) during periods of low Cdk activity.  Therefore, preRC components must be 
regulated throughout the cell cycle both during normal growth conditions and in 
response to DNA damage, through Cdk-independent pathways, to ensure genome 
stability is maintained.  This dissertation will discuss how Cdt1 and Cdc6 are 
regulated in response to both exogenous and endogenous forms of DNA damage. 
 
Cdt1 regulation following DNA damage 
One mechanism to ensure that origins are not re-licensed during low Cdk 
activity following DNA damage is through the degradation of Cdt1.  In response to 
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both ultraviolet (UV) and ionizing (IR) irradiation Cdt1 is rapidly degraded through a 
Cul4DDB1-dependent process (Figure 1.10A) [155, 164-167].  Like the cell cycle 
regulated ubiquitination of Cdt1 by Cul4DDB1, the DNA damage-induced degradation 
of Cdt1 requires an interaction between Cdt1 and PCNA [155, 165, 166].  PCNA is 
loaded onto DNA following DNA damage as part of the DNA repair process [158].  
Furthermore, Cdt1 mutants defective in PCNA binding display increased stability 
following DNA damage [155, 165].  Studies in Xenopus have shown that Cdt1 binds 
to PCNA on chromatin and the interaction between Cdt1 and PCNA is required for 
the ubiquitination of Cdt1 by Cul4DDB1 [150, 154].  However, no interaction between 
Cdt1 and chromatin has been observed in human cells following DNA damage. 
 
Cdc6 regulation following DNA damage 
The anaphase-promoting complex (APCCdh1) also targets Cdc6 for destruction 
in response to ionizing irradiation (IR) as part of a p53-dependent pathway.  In 
response to DNA damage, the upregulation of p53 induces p21 expression and 
inhibits the Cdk2 mediated phosphorylation of Cdc6 at serine-54.  The lack of Cdc6 
phosphorylation enables APCCdh1 to ubiquitinate Cdc6, targeting the protein for 
degradation [138].  Furthermore, suppression of p53 and p21 activity results in 
increased Cdc6 stability following DNA damage [138].   In addition, mutations to the 
APC recognition motifs, the Destruction-box and KEN motif, resulted in enhanced 
Cdc6 stability following IR [138].  However, the APC-p53 mechanism for Cdc6 
degradation does not hold true for other forms of damage, such as ultraviolet 
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radiation, and therefore is unlikely the only method for Cdc6 degradation after DNA 
damage (Figure 1.10B) [138].   
In response to treatment with the DNA alkylating agent adozelesin, Cdc6 is 
destroyed by a p53-independent and proteasome-dependent pathway [168].  In 
numerous cancers p53 is commonly inactivated; therefore a mechanism by which 
replication can be inhibited in cancers with deregulated p53 could be an important 
target for cancer therapeutics.  Interestingly, the APC-independent pathway of 
adozelesin-induced ubiquitination and degradation of Cdc6 has not been 
characterized, namely the ubiquitin ligase responsible has not been identified.  
Moreover, the D-Box, the APCCdh1 interacting motif, is not required for the DNA 
damage degradation in response to treatment with adozelesin, suggesting a 
mechanism independent of APC [168].  Furthermore, this APC-independent 
mechanism for Cdc6 degradation following DNA damage is conserved in budding 
yeast and the plant model, Arabidopsis thaliana, suggesting a conserved 
mechanism that uncouples DNA replication from the cell cycle following DNA 
damage [168].  In Chapter 2 I will further investigate the DNA damage-induced 
degradation of Cdc6 that is independent of APCCdh1.  In addition to ubiquitin-
mediated protein degradation, Cdc6 destruction also occurs as part of the caspase-
dependent apoptotic response (Figure 1.10B), and both the N- and C-terminus of 
Cdc6 contains caspase cleavage sites [169, 170]  
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REGULATION OF ORIGIN LICENSING DOES NOT RELY ON A SINGLE 
MECHANISM 
 
The pathways that prevent re-licensing of fired origins in naive and damaged 
cells are not completely understood.  What is clear is that cells go to great lengths to 
ensure replication occurs only once in a cell cycle and that improper licensing of 
origins after DNA damage does not occur.  There are many overlapping pathways to 
control preRC assembly in other organisms and therefore it is likely that there is 
more than one mechanism to regulate a given preRC component.  The existence of 
multiple mechanisms to inhibit rereplication suggests that any one mechanism by 
itself is inefficient in maintaining genome stability.  Furthermore, it has been shown 
that perturbations to multiple regulatory mechanisms are required to induce 
rereplication [87, 171].  The fact that Cdt1 is degraded in response to DNA damage 
would suggest Cdc6 should be regulated similarly to safeguard against re-licensing 
of origins.  Many of the preRC components are deregulated in cancers, presumably 
to maintain the high proliferation rate associated with cancer cells.  This dissertation 
will examine how replication is regulated in response to various forms of DNA 
damage and provide insight to the mechanisms that restrict DNA rereplication. 
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Figure 1.1. The Eukaryotic Cell Cycle. The eukaryotic cell cycle is divide into 4 
phases. G1 phase is when the cell prepares for DNA replication. DNA replication 
occurs during S phase.  G2 follows the completion of DNA replication and is 
when cells prepare for cell division.  During M phase, or mitosis, cells undergo 
cell division into two identical cells.
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Figure 1.2. Assembly of the prereplication complex (preRC).  The preRC 
assembles during G1 at replication origins.  PreRC formation occurs in a step-
wise manner and begins with the binding of the origin recognition complex (ORC) 
at origins.  Next, the replication factors Cdt1 and Cd6 are recruited independently 
to ORC, however both Cdt1 and Cdc6 must be present for the loading of the 
minichromosome maintenance (MCM) complex, the replication helicase.  Once 
these four components have assembled the origin is termed “licensed” for 
replication. 
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Figure 1.3. Origin re-licensing. (Left Panel) PreRCs license origins during G1, and 
DNA replication is initiated as cells transition into S phase.  (Right panel) Failure to 
restrict preRC assembly to G1 can result in the re-licensing of previously fired 
origins.  The re-licensing can result in rereplication (in red) leading to the formation of 
DNA double strand breaks.  Rereplication is a form of endogenous DNA damage and 
contributes to genome instability and tumorgenesis.  
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Figure 1.4. Regulation of preRC assembly.  To restrict preRC formation to G1 
components of the preRC components are regulated (A) through expression 
controlled by the E2F transcription factor, (B). the activity of cyclin-dependent 
kinases (C). and by ubiquitin mediated protein degradation.
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A. SCFSkp2 E3 ubiquitin ligase
B. Cul4DDB1 E3 ubiquitin ligase
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Figure 1.5. Protein ubiquitination by RING Finger E3 ubiquitin ligases.  
Model of the ubiquitination of a target protein by  two Skp-Cullin-F box protein 
family E3 ubiquitin ligases, (A) the Skp1-Cul1-Skp2 (SCFSkp2) ubiquitin ligase and 
(B) the DDB1-Cul4-Cdt2 (Cul4DDB1) ubiquitin ligase
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Figure 1.6. Cell cycle regulation of Cdc6.  The replication factor Cdc6 is 
regulated throughout the cell cycle through E2F-meidated expression and 
degradation in mitosis and G1 by the anaphase-promoting complex ubiquitin 
ligase (APCCdh1).  
33 
Cdt1
P
Cdk
geminin
E2F
Rb
PCNA
Cul4DDB1lSCFSkp2
Figure 1.7. Cell cycle regulation of Cdt1.  The replication factor Cdt1 is 
regulated throughout the cell cycle through Cdk-mediated phosphorylation, 
expression by E2, association with its inhibitor protein geminin, and ubiquitination 
by the SCFSkp2 and Cul4DDB1 ubiquitin ligase.
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Figure 1.8. The DNA damage checkpoint pathway.  In response to various 
forms of DNA damage the ATR/ATM checkpoint pathway is activated to halt cell 
cycle progression enabling the cell to repair any damage and prevent the 
accumulation of more damage to the genome.
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Figure 1.9. DNA damage removes a major mechanism to restrict preRC 
assembly.  Activation of the DNA damage checkpoint results in the inhibition of 
cyclin-dependent kinases, a major inhibitor of origin re-licensing (preRC 
assembly).  This low Cdk activity creates an environment that promotes new 
preRC assembly.  Therefore, it is important that preRC components are 
regulated in Cdk-independent manner during DNA damage.
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Figure 1.10. The regulation of Cdt1 and Cdc6  in response to DNA
damage. (A). Cdt1 is targeted for degradation in response to DNA damage 
through a mechanism dependent on the Cul4DDB1 ubiquitin ligase and an 
interaction between Cdt1 and PCNA.  (B). In response to ionizing radiation, 
Cdc6 is targeted for degradation through a mechanism that requires the 
anaphase promoting complex (APCCdh1).  However, Cdc6 is ubiquitinated 
and degraded in response to other forms of DNA damage through a 
mechanism that is independent of APCCdh1.  In addition Cdc6 is targeted for 
destruction by  caspase-mediated cleavage.
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INTRODUCTION 
Duplication of large mammalian genomes requires that DNA replication 
initiate at thousands of chromosomal origins. In order for an origin to be competent 
for replication, it must first be bound by a multi-protein complex, the prereplication 
complex (preRC). PreRCs are constructed in a stepwise process through the 
chromatin binding of the origin recognition complex (ORC), which then recruits both 
the Cdc6 ATPase and Cdt1, two proteins that are required for the stable loading of 
the minichromosome maintenance complex (MCM). The Cdc6 and Cdt1-dependent 
loading of MCM complexes at origins licenses them for replication during the G1 
phase of the cell cycle. Sufficient preRCs must be assembled during G1 to promote 
complete replication, but new preRCs must not assemble after S phase begins 
because re-licensing of previously fired origins leads to rereplication and genome 
instability [75, 80, 172, 173].  For these reasons, preRC assembly is one of the most 
highly regulated events in the control of DNA replication. Cells restrict preRC 
assembly to the G1 period through a combination of overlapping mechanisms that 
regulate individual preRC components (reviewed in [3, 96, 174-176]).  
Cdc6 is not only an essential factor for preRC construction, but it has also 
been implicated in the activation of the cell cycle checkpoint that prevents entry into 
mitosis while DNA replication is incomplete [56, 177].  These observations suggest 
that Cdc6 functions not only during G1, but also in later cell cycle stages. Moreover, 
Cdc6 plays a role in setting the threshold for commitment to apoptosis [114, 169, 
170]. These findings suggest that the regulation of Cdc6 has important 
consequences for multiple aspects of cell cycle control and cell fate determination. In 
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addition, the high levels of Cdc6 protein observed in multiple cancers may contribute 
to cell cycle regulation defects and genome instability that consequently promote 
tumor progression [81, 178-181]. 
Cdc6 is subject to multiple forms of regulation, including both transcriptional 
and posttranscriptional mechanisms. The human CDC6 gene is regulated by the Rb-
E2F transcriptional program that results in peak CDC6 mRNA levels in late G1 [93, 
182, 183]. The Cdc6 protein is degraded each cell cycle in early G1 as a 
consequence of ubiquitination by the Cdh1-activated form of the anaphase 
promoting complex (APC), a cell cycle–regulated ubiquitin E3 ligase [135]. 
Ubiquitination of Cdc6 by APCCdh1 is regulated not only by cell cycle–dependent 
fluctuations in APC activity, but also by phosphorylation of Cdc6 by cyclin-dependent 
kinases, most notably cyclin E/Cdk2. Cdk2-mediated phosphorylation blocks the 
association of Cdc6 with the Cdh1 protein, thus stabilizing Cdc6 when Cdk2 is active 
[126, 138] . 
Cdc6 is also ubiquitinated and degraded in response to DNA damage [138, 
168]. Cells may eliminate Cdc6 to reduce the possibility of rereplicating DNA or to 
promote checkpoint functions that block mitosis with damaged DNA. One 
mechanism to ubiquitinate Cdc6 relies on inhibition of Cdk2 during a checkpoint 
response as a result of p53-mediated induction of the p21 Cdk inhibitor. Reduced 
Cdk2 activity destabilizes Cdc6 because it is no longer protected from ubiquitination 
by APCCdh1 [138]. However, this pathway does not fully account for the degradation 
of Cdc6 after DNA damage.  p53 is not required for Cdc6 degradation after UV 
irradiation or after treatment of cells with various DNA-alkylating agents such as 
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adozelesin or methyl methane sulfonate (MMS; [168]).  Importantly, APC activity 
itself is inhibited during S phase and G2, times when it may be particularly important 
to regulate Cdc6 in order to prevent rereplication or to promote checkpoint 
activation. These observations implicate an as yet unidentified APC-independent 
pathway for degradation of Cdc6. We sought to determine this p53- and APC-
independent mechanism of Cdc6 degradation, and we report here our finding that 
Cdc6 stability after DNA damage is controlled by a novel ubiquitin ligase, Huwe1. 
 
MATERIAL AND METHODS 
Growth and manipulation of cells 
HeLa, NHF1-hTERT [184], and U-2OS cells were cultured in DMEM 
(Invitrogen) with 10% fetal calf serum (Sigma). MMS, MG132 (Z-Leu-Leu-Leu-H), 
nocodazole, and cycloheximide (CHX) were purchased from Sigma. UV irradiation 
was performed using a germicidal UV-C (254-nm) lamp (General Electric) or 
alternatively by treatment of phosphate-buffered saline (PBS)-washed cells in a 
Stratalinker (Stratagene). The endogenous Cdc6 locus in both the yeast strain 
BY4741 and its isogenic derivative tom1::G418 (Invitrogen) was tagged at the 3' end 
of the cdc6 open reading frame with 13 tandem copies of the myc (9E10) epitope by 
the method of Longtine et al. [185] to yield strains JCY200 (wt) and JCY201 (tom1 ), 
respectively1. The tom1 deletion was confirmed by the temperature-sensitive growth 
at 37°C (data not shown).  
 
 
                                             
1 Yeast strains were constructed by K. Scott Luce 
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Small interfering RNA 
Small interfering (siRNA) targeting Huwe1 (5'-
GAGUUUGGAGUUUGUGAAGTT-3'), human Cdh1 (5'-
UGUGAAGUCUCCCAGUCAGTT-3'), and the negative control green fluorescent 
protein (GFP; 5'-GGCUACGUCCAGGAGCGCACCTT-3') were synthesized by 
Invitrogen and transfected at a final concentration of 100 nM using Dharmafect 
Reagent 1 (Dharmacon).  DDB1, Cul4A, and Cul4B siRNA were described in Hu et 
al [164].; geminin siRNA was described in Ballabeni et al. [186].  
 
Antibodies and immunoblots 
Anti-Cdc6 (sc-9964), Anti-Cdc6 (D-1), anti-cyclin A (C-19), anti-c-Myc (sc-40), 
anti-hemagglutinin (Y-11), anti-p53 (D01), anti-ScMcm2 (yN-19), anti-geminin (FL-
209) were purchased from Santa Cruz Biotechnology, anti-cyclin B1 (V152) from Lab 
Vision, anti-Cdh1 (DH01) from Biomeda , anti-Orc2 from BD PharMingen, and anti-
tubulin (DM1A) from Sigma. Phosphospecific antibodies to p53 phosphorylated on 
Ser15 and Chk2 phosphorylated on T69 were purchased from Cell Signaling 
Technologies.   Anti-Huwe1 (anti-Lasu1, BL671) was purchased from Bethyl 
Laboratories (for immunoprecipitations) or was the gift of S. Wing (McGill 
University)([187]; for immunoblots). Anti-Cul4 and anti-DDB1 antibodies were the gift 
of Y. Xiong (University of North Carolina at Chapel Hill); anti-yeast phosphoglycerate 
kinase (PGK) was a gift of H. Dohlman (University of North Carolina at Chapel Hill). 
Relative Cdc6 abundance was determined by densitometric analysis of light 
exposures of immunoblots using the ImageJ program (W. S. Rasband, ImageJ, 
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National Institutes of Health, Bethesda, MD; http://rsb.info.nih.gov/ij/, 1997–2006). 
The ratio of Cdc6 signal to tubulin signal (after background subtraction) is reported 
as the mean of two or more experiments. 
 
Two-hybrid screen2   
The Gal4 DNA-binding domain was inserted at the carboxy terminus of 
human Cdc6 through a PCR strategy and expressed from the GPD promoter in 
plasmid p2U (gift of D. Picard, Université de Genève). Cotransformants of strain 
PJ69a with one of two cDNA fusion libraries (placental cDNA or thymus cDNA, 
Clontech) were selected on medium containing 3 mM 3-amino-1,2,4 triazole (Sigma). 
More than 8 million co-transformants of each library were screened; Huwe1 clones 
were identified from both libraries.   
 
Plasmids and viruses 
A fragment encoding the carboxy-terminal 388 residues of Huwe1 (Huwe1C; 
GenBank Accession BC063505) was subcloned into pDONOR221 (Invitrogen), 
followed by recombination into the glutathione S-transferase (GST) expression 
vector pDEST15 (Invitrogen). Adenovirus directing production of myc-epitope tagged 
Cdc6 has been described [33]. Cdc6S3D was constructed by J.G Cook using site-
directed mutagenesis of serines 54, 74, and 104 to aspartic acid in a construct that 
also bears a strong N-terminal nuclear localization signal (NLS) from SV40 T 
antigen. A Cdc6S3D mutant adenoviral construct without the NLS the mutation 
                                             
2 Two-hybrid screen was performed by Evelyn Kow and Jeanette Gowen Cook 
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expresses a constitutively cytoplasmic protein that is stable in quiescent cells (Cook, 
unpublished observations). Cdc6WT bears the same NLS fusion.  
 
In vitro protein-binding assay 
GST-Huwe1C was produced in BL21(DE3) purified on glutathione-Sepharose 
(GE Healthcare, Waukesha, WI) and incubated with cell lysates prepared in buffer 1 
(50 mM HEPES, pH 7.2, 33 mM potassium acetate, 0.5 mM EDTA, 0.5 mM EGTA, 
0.1% Nonidet P-40, 10% glycerol, and protease and phosphatase inhibitors) 
essentially as described in Cook et al. [22]. GST-hCdc6 was produced by infection of 
SF21 insect cells with GST-hCdc6 baculovirus and purification of GST-hCdc6 was 
performed as described in Herbig et al. [27].  
 
Co-immunoprecipitation 
 HeLa cell nuclei were prepared by hypotonic lysis followed by brief sonication 
in S7 nuclease-containing buffer 1 supplemented with 1 mM CaCl2. To aid Cdc6 
solubility, NaCl was added to 250 mM for 5 min and then diluted to 45 mM. Portions 
of clarified lysate were reserved on ice, and the remainder was mixed with 3 µg of 
anti-Huwe1 (BL671) or normal rabbit serum at 4°C for 1 h. Lysates were centrifuged 
for 5 min at 13,000 x g, and supernatants were incubated with Protein A agarose 
(Roche, Indianapolis, IN) for an additional hour. Immune complexes were washed 
twice with buffer 1. Bound proteins were solubilized in 2x Huwe1 sample buffer (50 
mM Tris, pH 6.8, 8 M urea, 75 mM dithiothreitol, 3% SDS, 0.05% Bromophenol blue) 
heated at 37°C for 5 min, and resolved by SDS-PAGE.  
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Chromatin fractionations 
Nuclei were prepared from whole cell lysates by resuspenation of HeLa cells 
in CSK buffer (10 mM PIPES pH 7.0, 100 mM NaCl, 200 mM sucrose, and 3 mM 
MgCl2) supplemented with 0.5% Triton-X100, 10 mM AEBSF (CalBiochem), 1 µg/ml 
pepstatin A (Sigma), 1 µg/ml leupeptin (Sigma), 1 µg/ml aprotinin (Sigma), 0.5 mM 
sodium orthovanadate (Sigma), 1 mM glycerol 2-phosphate (Sigma), 10 µg/ml 
phosvitin (Sigma) and 1 mm ATP (Sigma) followed by low-speed centrifugation.  
Micrococcal nuclease (Roche) digestion was performed at 37°C for 5 minutes to 
release chromatin bound proteins. 
 
In vitro ubiquitination assay3
In a 10-µl reaction, 100 ng of purified recombinant GST-Cdc6 was incubated 
with an ATP-regenerating system (50 mM Tris, pH 7.6, 5 mM MgCl2, 5 mM ATP, 10 
mM creatine phosphate, 3.5 U/ml creatine kinase), 10 µg ubiquitin, 10 ng human E1, 
100 ng Ubch7, and Huwe1 as indicated at 37°C for 2 h in a manner similar to that 
described in Zhong et al. [188]. After terminating the reactions with SDS sample 
buffer, reaction products were fractionated by SDS-PAGE (6%) and analyzed by 
immunoblotting with anti-Cdc6 antibody (D-1, Santa Cruz) at 1:4000 dilution.   
 
 
 
 
                                             
3 In vitro ubiquitination assays were performed by Chiajung Karen Lu in the laboratory of Dr. 
Qing Zhong at the University of California, Berkeley.  
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RESULTS 
An APC-independent mechanism for Cdc6 degradation 
          To explore the regulation of Cdc6 after DNA damage, we treated an 
asynchronous population of HeLa cells with MMS or with UV irradiation. Similar to 
previous results (Blanchard et al., 2002), both kinds of DNA damage resulted in 
significant loss of endogenous Cdc6 (Figure 2.1 A, compare lanes 2 and 3 with lane 1), 
and the degradation was sensitive to proteasome inhibition by MG132 (Figure 2.1A, 
lanes 4–6). Under these conditions, we did not observe the caspase cleavage product of 
Cdc6 after DNA damage (data not shown); this cleavage normally occurs 12 h after 
induction of apoptosis [170]. 
We next compared the kinetics of Cdc6 degradation in HeLa cells and in normal 
human fibroblasts (NHF; Figure 2.1B4) to determine if differences in Cdc6 regulation 
might contribute—along with deregulated transcription—to the high levels of Cdc6 
observed in cancer cells [81, 178, 179]. For this experiment, defined numbers of actively 
growing, subconfluent cells were analyzed for endogenous Cdc6 at various times after 
UV treatment. Whole cell extracts were prepared from 6 x 104 HeLas or 1.2 x 105 NHFs, 
in order to compare the relative amounts of Cdc6 remaining at each time after UV 
treatment.  The overall rate of Cdc6 loss was similar in both cell lines (Figure 2.1B). 
However, HeLa cells consistently harbor at least 10-fold higher levels of Cdc6 per cell 
than NHFs (Figure 2.1B, compare lanes 1 and 7).  Because of these high initial levels, 
even 3 h after DNA damage HeLa cells still contained at least as much Cdc6 as the 
untreated normal cells (Figure 2.1B, compare lanes 6 and 7).  The amount of Cdc6 in 
naive normal cells is clearly enough to support a complete round of genomic DNA 
                                             
4  Figure 2.1B was generated by Kathleen R. Nevis 
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replication; thus cancer cells with high levels of Cdc6 have a relatively long period of 
abundant Cdc6 after DNA damage. 
We specifically tested if Cdc6 overproduction could suppress DNA damage–
induced Cdc6 degradation by overwhelming the capacity of the cells to target the 
excess protein. We infected U-2OS cells with either control adenovirus or virus-
producing Cdc6 at either moderate doses or high doses and then treated cells with 
MMS to induce Cdc6 degradation. Both the ectopic and endogenous Cdc6 proteins 
were detected by immunoblot analysis. At the lower viral dose, ectopic Cdc6 
accumulated to three times that of endogenous Cdc6 as estimated by densitometry 
(data not shown), and though it was reduced by DNA damage, some ectopic Cdc6 
protein still remained (Figure 2.1C, lanes 3 and 4). Increasing the level of ectopic 
Cdc6 further to approximately six times that of endogenous Cdc6 significantly 
impaired the ability of these cells to degrade Cdc6 in the presence of MMS, but had 
no effect on the DNA damage–induced degradation of Cdt1 (Figure 2.1C, lanes 7 
and 8). 
To determine if high levels of Cdc6 can induce rereplication, we overproduced 
Cdc6 in cells arrested in G2. Extensive rereplication is associated with an activated 
cell cycle checkpoint characterized by phosphorylation of both the p53 tumor 
suppressor and the Chk2 protein kinase. These markers are strongly induced by 
depletion of geminin, a negative regulator of preRC assembly that inhibits Cdt1 (Zhu 
et al., 2004 ; Figure 2.1D, lane 3). We infected HCT116 (p53+) cells with a high 
dose of Cdc6-producing adenovirus and held these cells in nocodazole for 20 h to 
block mitosis. Under these conditions, Cdc6 accumulated to 12 times that of 
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endogenous Cdc6 (data not shown). High levels of Cdc6 induced phosphorylation of 
both Chk2 and p53 (Figure 2.1D, compare lanes 1 and 2). Moreover, Cdc6 
overproduction was sufficient to cause rereplication detectable as an increase in the 
number of cells with greater than 4C DNA content (Figure 2.1D). Depletion of 
geminin caused robust rereplication as had been reported by others [80, 189, 190],  
and the combination of high levels of Cdc6 with geminin depletion increased the 
number of rereplicating cells even further (Figure 2.1D, numbers 3 and 4). We thus 
conclude that Cdc6 de-regulation can promote rereplication, and that the 
degradation of both Cdc6 and Cdt1 after DNA damage may be important for 
maintaining genome integrity. 
Because persistent Cdc6 might contribute to genome instability we sought to 
understand the mechanism of DNA damage-induced Cdc6 degradation. To 
determine if Cdc6 degradation is affected by cell cycle stage, we synchronized U-
2OS cells at G2/M by sequential treatment with thymidine and nocodazole followed 
by release from the arrest; cell cycle position was confirmed by flow cytometry 
(2.2A). In undamaged cells endogenous Cdc6 protein was low in G1 and 
accumulated throughout S phase and G2, as expected. Strikingly, DNA damage–
induced Cdc6 degradation at every stage of the cell cycle despite the presumed 
inhibition of APC after the G1/S transition (Figure 2.2B). 
APC-mediated Cdc6 degradation is blocked when Cdc6 is phosphorylated by 
Cdk2. Mutational alteration of the Cdk target sites to aspartic acid mimics 
phosphorylation and blocks interaction with APC [126, 138]. Thus, if Cdc6 
degradation after UV or MMS treatment occurred by promoting dephosphorylation of 
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Cdc6 and sensitizing Cdc6 to APC, then these aspartic acid substitutions would 
prevent Cdc6 degradation. To test this possibility, we constructed adenoviral vectors 
to produce myc-epitope–tagged versions of both normal Cdc6 (WT) or Cdc6 in which 
the Cdk target sites, serines 54, 74, and 104, were altered to aspartic acid, Cdc6S3D 
5. Low doses of these viruses were used to infect HeLa cells such that the level of 
ectopic Cdc6 was less than endogenous Cdc6. UV irradiation caused the 
degradation of not only the endogenous Cdc6 (Figure 2.3A, lanes 1 and 2), but also 
the ectopically expressed Cdc6 (Figure 2.3A, lanes 3 and 4). Moreover, the S3D 
mutant showed equal susceptibility to UV-induced degradation (Figure 2.3A, lanes 5 
and 6), indicating that phosphorylation at these serine residues does not control DNA 
damage-induced Cdc6 degradation. 
Cdc6 ubiquitination by APC requires the targeting subunit, Cdh1 [135, 138]. It 
was possible that during a DNA damage response, Cdc6 became more APC-sensitive 
by some mechanism other than dephosphorylation at the known Cdk sites. To 
definitively demonstrate that Cdc6 degradation can occur independently of APCCdh1, we 
eliminated Cdh1 in cells by siRNA transfection. Effective knockdown of Cdh1 was 
confirmed by immunoblot analysis and the resulting accumulation of cyclin B (Figure 
2.3B). Despite the depletion of Cdh1, Cdc6 degradation after MMS treatment was 
unaffected (Figure 2.3B, compare lanes 2 and 4). APC-mediated ubiquitination of Cdc6 
after ionizing radiation requires p53 [138], but we observed no difference between 
normal human fibroblasts and isogenic cells deficient in p53 with regard to their ability to 
degrade Cdc6 after MMS treatment (Figure 2.3C), consistent with earlier findings in 
tumor cell lines lacking functional p53 [168]. Degradation of Cdc6 occurred despite the 
                                             
5 Adenoviruses were constructed by Jeanette Gowen Cook 
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fact that naive p53-deficient cells have higher endogenous Cdc6 levels, presumably 
because of the combined effects of the p53-dependent deregulation of Cdks on both 
E2F-dependent CDC6 transcription [93, 191] and APC-dependent Cdc6 protein stability 
during G1 [126, 138]. We thus conclude that DNA damage induces Cdc6 degradation 
regardless of cell cycle position, APC activity, or p53 status. 
Like Cdc6, Cdt1 is ubiquitinated and degraded after DNA damage. 
Ubiquitination of Cdt1 under these conditions is dependent on the Cul4DDB1 ubiquitin 
ligase [164, 167]; thus it was possible that Cul4 also ubiquitinated Cdc6 after DNA 
damage. However, cells treated with siRNAs targeting both Cul4A and Cul4B 
showed no difference in the degradation of Cdc6 after MMS treatment (Figure 2.4A, 
compare lanes 1 and 2 with lanes 3 and 4). Reduction of DDB1 by a similar siRNA 
strategy significantly delayed the normally rapid destruction of Cdt1 (Figure 2.4B, 
compare lanes 2 and 6), though the remaining DDB1 was capable of eliminating 
Cdt1 by later time points. (This hypomorphic phenotype is typical of DDB1-depleted 
cells; J. Hu and Y. Xiong, personal communication.) Importantly, UV-irradiated cells 
in which DDB1 is reduced by siRNA treatment degraded Cdc6 with the same kinetics 
as control cells (Figure 2.4B, compare lanes 1–4 with lanes 5–8). We thus 
hypothesized that an entirely different ubiquitin ligase plays an important role in Cdc6 
ubiquitination and degradation in response to DNA damage.  
 
Interaction of Cdc6 with Huwe1 
           We identified multiple isolates of a 4374 amino acid ubiquitin E3 ligase in a 
two-hybrid screen for proteins that interact with Cdc6 (Figure 2.5A). This enzyme is a 
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member of the HECT family and can ubiquitinate the Mcl-1 anti-apoptotic protein, 
core histones, the c-myc transcription factor, and the p53 checkpoint mediator. 
These reports named the enzyme Mule [188, 192], Lasu1 [187], HectH9 [193], and 
ARF-BP1 [194], respectively. We use the official gene name, HUWE1 for "HECT, 
UBA and WWE domain containing 1" (gene ID 10075) and refer to the protein as 
Huwe1. All of our two-hybrid isolates contain portions of the carboxy-terminal 
catalytic domain of Huwe1 (Figure 2.5C). Interestingly, this sequence is distinct from 
both the reported myc-interaction region of Huwe1 just amino-terminal to the HECT 
domain [193] and the BH3 motif at amino acids 1972–1999, which binds Mcl-1 [188, 
192]. We constructed derivatives of the Cdc6 two-hybrid fusion in which increasing 
amounts of the amino terminal (non-catalytic) domain were deleted and tested them 
for interaction with the Huwe1 fusions. Removal of as many as the first 154 amino 
acids, but not the first 192, from Cdc6 had no effect on the two-hybrid interaction of 
Cdc6 with Huwe1, demonstrating that this region is dispensable for the Cdc6-Huwe1 
interaction (Figure 2.5B). We note that the catalytic domain of Cdc6 is the most 
highly conserved domain and is included in the constructs that retain binding to the 
most highly conserved domain of Huwe1. 
We confirmed that Cdc6 and Huwe1 interact biochemically. For this purpose, we 
produced a fusion of GST to the c-terminal domain of Huwe1 (amino acids 3987–4374 
"GST-Huwe1C") in Escherichia coli. Glutathione beads coated with GST or GST- 
Huwe1C were incubated with a lysate of HeLa cells expressing epitope-tagged Cdc6 
(myc5-Cdc6). Under these conditions, Cdc6 bound to Huwe1, but not to GST control 
beads (Figure 2.6A, compare lanes 2 and 3). Furthermore, GST-Cdc6 produced in 
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insect cells co-precipitates endogenous full-length Huwe1 from HeLa cell extracts 
(Figure 2.6B, compare lanes 2 and 3). To determine if these proteins can bind in the 
absence of other cellular proteins (human or yeast), we mixed purified recombinant 
Cdc6 with glutathione beads coated with purified recombinant GST-Huwe1C. Cdc6 was 
specifically retained on these beads, indicating that these two proteins can interact 
directly (Figure 2.6C). 
Finally, we tested if Huwe1 and Cdc6 associate when they are expressed at 
their endogenous levels. To determine if Huwe1 and Cdc6 interact during a DNA 
damage response, we irradiated cells with UV (or left them untreated) and then 
added MG132 to block the degradation of Cdc6. We prepared nuclear lysates from 
HeLa cells and released Cdc6 from chromatin with nuclease. These extracts were 
subjected to immunoprecipitation with anti-Huwe1 antibodies and then probed for 
endogenous Cdc6. Cdc6 was found in Huwe1 immunoprecipitates both in the 
absence and in the presence of DNA damage (Figure 2.6D, lanes 5 and 6). 
If Huwe1 is the ubiquitin ligase that controls Cdc6 degradation, then Huwe1 
should be able to ubiquitinate Cdc6. We therefore tested the ability of full-length (492 
kDa) recombinant Huwe1 purified from insect cells [188] to polyubiquitinate 
recombinant Cdc6 in vitro6. We incubated purified GST-Cdc6 with Huwe1 in the 
presence of E1 and E2 enzymes and ubiquitin under conditions similar to those 
initially defined for ubiquitination of the Mcl-1 protein by Huwe1 (a.k.a. Mule;[188]). 
Substantial poly-ubiquitination of Cdc6 was detected by immunoblot analysis of the 
reaction products, and the ubiquitination was dependent on the concentration of 
                                             
6 In vitro ubiquitination assay was performed by Chiajung Karen Lu in the laboratory of Dr. Qing 
Zhong. 
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Huwe1 (Figure 2.6E, compare lanes 2–4). These results suggest that Huwe1 binds 
Cdc6 for the purpose of catalyzing Cdc6 ubiquitination and that Huwe1 may play a 
role in Cdc6 stability in cells. 
 
Huwe1-dependent regulation of Cdc6 stability in cells 
 
Huwe1 is not induced by DNA damage (Figures 2.6D and 2.7, A, B, and D) 
suggesting that some mechanism other than enhanced expression must operate to 
promote Cdc6 ubiquitination after DNA damage. To explore how Cdc6 becomes 
unstable after DNA damage, we tested if Cdc6 chromatin association is affected by 
DNA damage. HeLa cells were UV irradiated and harvested at different times after 
UV treatment up to 3 h. Additional cells were simultaneously treated with UV 
irradiation and MG132 to block Cdc6 degradation. Nonionic detergent insoluble 
pellets were prepared from these cells, and DNA-bound proteins were released from 
these pellets with micrococcal nuclease. Proteins released by nuclease digestion 
were defined as the chromatin-bound proteins, and their abundance was compared 
with their overall abundance in portions of the starting whole cell lysates. In naive 
HeLa cells, Cdc6 is readily detected in chromatin fractions (Figure 2.7A, lanes 1 and 
8). Within 30 min after UV treatment, the amount of Cdc6 remaining on chromatin 
was substantially reduced (Figure 2.7A, compare lanes 8 and 9), even though at this 
early time point the overall amount of Cdc6 in the whole cell lysate was still largely 
unchanged (Figure 2.7A, compare lanes 1 and 2). Most strikingly, when Cdc6 
degradation was blocked with MG132, the overall level of Cdc6 protein remained 
unchanged, as expected (Figure 2.7A, compare lanes 1 and 7), but the amount of 
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chromatin bound Cdc6 was almost undetectable (Figure 2.7A, compare lanes 8 and 
14). Importantly, Huwe1 itself is not appreciably associated with chromatin either 
before or after DNA damage (Figure 2.7A, lanes 8–14). These data suggest that 
Cdc6 is released from chromatin after DNA damage into the soluble fraction where it 
can associate with the soluble Huwe1. This mechanism of induced interaction was 
not detectable in the co-immunoprecipitation experiments in Figure 2.6D because 
Cdc6 required solubilization by nuclease digestion of the lysates before 
immunoprecipitation. 
To test if Huwe1 is required for the degradation of Cdc6 in cells, we designed 
siRNA molecules to target the Huwe1 mRNA. Cells transfected with Huwe1 siRNA 
showed significant knockdown of endogenous Huwe1 protein after 48 h (Figure 
2.7B, middle panel, compare lanes 1–3 with lanes 4–6).  Asynchronous cells 
transfected with control siRNA rapidly degraded Cdc6 after DNA damage induced by 
UV, but cells with reduced Huwe1 did so considerably less efficiently (Figure 2.7B, 
top panel, compare lanes 1–3 with lanes 4–6).  This result is similar to the effects of 
DDB1 knockdown on Cdt1 stability after DNA damage (Figure 2.4B) in that Huwe1-
depleted cells are hypomorphic for Cdc6 degradation. 
If reduction of Huwe1 induced a delay or arrest in G2, then Cdc6 levels might 
simply have been higher as a consequence of an indirect cell cycle effect.  However, 
duplicate cultures treated with Huwe1 siRNA and analyzed by flow cytometry 
showed no differences in cell cycle distributions (Figure 2.7C).  When we cultured 
cells lacking Huwe1 for an additional 3 days, we noted a significant proliferation 
defect, in keeping with reports by others (Figure 2.7C)[193], but we observed no 
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apparent changes in cell cycle distribution compared with control cultures even at 5 
days after transfection (data not shown). The growth arrest is not associated with 
robust changes in Cdc6 (data not shown), but may be explained by deregulation of 
other Huwe1 substrates such as c-myc and Mcl-1 [188, 192-194]. We thus conclude 
that the increased Cdc6 in UV-treated cells as a consequence of the loss of Huwe1 
is not a reflection of a cell cycle arrest, but rather a more direct effect on steady-state 
Cdc6 abundance. 
Two-thirds of the asynchronous Huwe1-depleted cells in Figure 2.7B were in 
G1 (Figure 2.7C). Presumably these cells contained active APC, which may have 
contributed to Cdc6 ubiquitination in the absence of Huwe1. To focus specifically on 
the APC-independent degradation of Cdc6, we arrested cells in S phase by 
treatment with thymidine. In thymidine-arrested cells in the absence of DNA damage, 
Cdc6 is stable because APC in inactive. This assertion is supported by the 
observation that treatment of S phase cells with the proteasome inhibitor MG132 had 
no effect on Cdc6 abundance. In response to DNA damage, however, S phase cells 
degraded Cdc6 after UV or MMS treatment (Figure 2.7D, compares lanes 2 and 3 to 
lane 1). In marked contrast, we observed much less degradation of Cdc6 after DNA 
damage caused by either UV or MMS in Huwe1-depleted cells (Figure 2.7D, 
compare lanes 5 and 6 to lane 4). Reduction of Huwe1 with a different siRNA 
molecule had the same effect (data not shown). 
It was possible that Huwe1 regulated Cdc6 abundance by indirectly controlling 
Cdc6 transcription or translation. We occasionally (though not consistently) observed 
an increase in Cdc6 abundance after Huwe1 depletion even in the absence of 
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exogenous damage (for instance, Figure 2.7B, compare lanes 1 and 4). The fact that 
Cdc6 is not normally ubiquitinated in S phase–arrested cells suggests that Huwe1 
depletion may have affected Cdc6 levels before the arrest so that they arrived in S 
phase with more Cdc6. It is also possible that endogenous sources of DNA damage 
may restrict Cdc6 abundance through Huwe1. Alternatively Huwe1 may regulate 
Cdc6 synthesis indirectly through transcriptional mechanisms involving other Huwe1 
substrates such as c-myc or p53. To distinguish effects of Huwe1-depletion on Cdc6 
stability from effects on Cdc6 synthesis, we treated control cells or Huwe1-depleted 
cells with cycloheximide (CHX) to block new protein synthesis. We monitored the 
loss of Cdc6 after treatment of thymidine-blocked HeLa cells with both UV irradiation 
and CHX. In CHX-treated cells, Cdc6 was degraded after UV irradiation (Figure 2.8A, 
lanes 1–4), demonstrating that upregulation of UV-induced genes is not required for 
Cdc6 degradation after DNA damage. Depletion of Huwe1 had no effect on the 
degradation of Cdt1 (Figure 2.8B) or on the accumulation of p53 (Figure 2.8C), 
indicating that Huwe1 depletion does not interfere with the DNA damage response. 
Importantly, Cdc6 persisted in UV-irradiated Huwe1-deficient cells even in the 
presence of CHX (Figure 2.8A, compare lanes 2–4 with lanes 6–8). This result 
demonstrates that Huwe1 is required for Cdc6 degradation per se and that any 
potential indirect effects of Huwe1 that might have occurred through transcriptional 
regulation of CDC6 or other genes cannot account for the persistence of Cdc6 after 
DNA damage. The defect in Cdc6 degradation was most dramatic in the first hours 
after irradiation; the remaining Huwe1 was presumably capable of supporting some 
Cdc6 degradation over the full course of 4 h, though even at this late time point, 
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more Cdc6 persists in Huwe1-deficient cells than in control cells (Figure 2.8A). 
During the initial 2 h after UV treatment the half-life of Cdc6 increased from 1.2 h in 
control cells to 4.7 h in cells with reduced Huwe1 (Figure 2.8A, compare lanes 4 and 
8). Therefore, Huwe1 is required for Cdc6 degradation after DNA damage at times 
when APC is inactive.  
 
Conservation of Huwe1-dependent regulation of Cdc6 
            Huwe1 is an evolutionarily conserved ubiquitin ligase; similar sequences 
containing not only a C-terminal catalytic domain, but also the two N-terminal 
conserved domains of unknown function (DUF908 and DUF913, Figure 2.4A) not 
present in other HECT family ligases are identifiable in the genomes of plants, flies, 
worms, and yeast. In the budding yeast Saccharomyces cerevisiae, the Huwe1 
ortholog is Tom1 for temperature-dependent organization in mitotic nucleus (distinct 
from the human Tom1 protein, target of Myb1). Yeast Tom1, like Huwe1, has been 
proposed to have multiple nuclear substrates, and tom1 mutants are temperature-
sensitive for growth at 37°C [195, 196]. To test if the Huwe1-dependent degradation 
of Cdc6 is similarly conserved in budding yeast, we constructed isogenic wild-type 
and tom1 deletion strains in which the endogenous cdc6 gene has been modified to 
include 13 tandem copies of the myc epitope7. Cultures of these strains were grown 
at 30°C (the permissive temperature), and then treated with MMS. Wild-type yeast 
cells degraded Cdc6-myc within 60 min, but showed no loss of endogenous yeast 
Mcm2 or PGK (Figure 2.9A, lanes 1–3). Deletion of the Huwe1 ortholog, tom1, 
                                             
7 Isogenic yeast strains were constructed by K. Scott Luce 
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resulted in somewhat increased Cdc6 in naive cells, but importantly, significantly less 
Cdc6-myc degradation in the presence of MMS (Figure 2.9A, lanes 4–6). 
At the nonpermissive temperature (37°C), tom1 mutants display a G2/M arrest 
accompanied by defects in protein synthesis [196]. To rule out effects on Cdc6 
abundance due to potential cell cycle changes that might have manifested even at 
the permissive temperature, we monitored the budding of both wild-type and tom1 
strains grown at 30°C. We found no differences in the relative numbers of unbudded, 
small-budded, or large-budded cells, and we observed only minor differences in the 
overall growth rate at 30°C (data not shown). Given these observations, plus the fact 
that yeast Cdc6 is most abundant in G1 rather than G2 [18, 123], it seems unlikely 
that the enhanced levels of Cdc6 were due to roles of Tom1 in G2/M progression or 
protein synthesis. These results indicate that Tom1 is required for degradation of 
yeast Cdc6 after DNA damage and suggest that the regulation of Cdc6 abundance 
by Huwe1-type ubiquitin ligases is conserved. 
 
DISCUSSION 
Taken together, the results presented here indicate that Cdc6 ubiquitination 
induced by both UV irradiation and by DNA alkylation can be carried out by the 
Huwe1 enzyme. This study complements previous work on the cell cycle– and 
ionizing radiation–induced ubiquitination of Cdc6 carried out by APCCdh1 [126, 135, 
138].  The demonstration of two independent ubiquitin ligases for Cdc6 is another 
example of a common theme in cell cycle regulation, namely multiple overlapping 
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regulatory mechanisms. Presumably these multiple pathways evolved to ensure tight 
control over essential processes under a variety of conditions. 
DNA damage sufficient to induce Cdk2 inhibition can accelerate Cdc6 
degradation by inhibiting the protective phosphorylation at Ser54, but this 
mechanism can only operate when APC is active [138]. On the other hand, we find 
that Huwe1 ubiquitination of Cdc6 can occur in S phase, even when Cdc6 has been 
altered to mimic phosphorylation by Cdk2. Therefore, like Cdt1, which associates 
with two different ubiquitin ligase complexes, Skp2 and Cul4 [124, 125, 146, 147, 
155, 165, 197], Cdc6 is regulated by both APC and Huwe1. Because the human 
genome contains many thousands of potential origins, these different control 
pathways may be required to prevent re-licensing at even a small percentage of 
origins. Multiple mechanisms may also need to be in place to adequately respond to 
a variety of cellular insults. 
DNA damage activates an intracellular signaling pathway that culminates in 
cell cycle checkpoint arrest through inhibition of Cdks [158, 159]. If the damage 
occurs during S phase or G2 and is subsequently repaired (instead of inducing 
apoptosis), then cells could recover with new preRCs on the already duplicated 
DNA. Even though geminin is not degraded after DNA damage ([167] and our 
unpublished observations), the persistence of geminin during a checkpoint response 
is not sufficient to block substantial preRC reassembly. This assertion is supported 
by previous findings that direct inhibition of Cdk activity during G2, either 
pharmacologically or genetically, permits reloading of MCM proteins onto chromatin 
even in the presence of geminin [186, 198]. Thus, there is a risk of genome instability 
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if preRCs are permitted to assemble while Cdk activity is inhibited. Presumably to 
guard against this threat, both Cdc6 and Cdt1 are actively degraded after DNA 
damage, and we suggest that the degradation during S phase and G2 is particularly 
important. 
The Huwe1-dependent mechanism of Cdc6 degradation after DNA damage 
caused by UV radiation or MMS is distinct from the APCCdh1-dependent mechanism 
of Cdc6 degradation caused by ionizing radiation (IR). Substantial IR-induced Cdc6 
degradation is only observed in p53-proficient cells and requires induction of p21 
expression [138]. In contrast, Cdc6 degradation induced by UV radiation, MMS, or 
adozelesin (another DNA alkylating compound) occurs equally well in both p53-
proficient and p53-deficient cells (Figure 2.3C and [168]). The cellular response to IR 
is primarily mediated by the ATM and Chk2 kinases that are stimulated by double-
strand DNA breaks. On the other hand, most other forms of DNA damage, including 
UV and MMS-induced damage, primarily trigger activation of the ATR and Chk1 
kinases. These two kinase cascades are related but distinct in both the signals that 
trigger their activation and in their primary substrates. It is possible that differences in 
the kinase pathways that are activated by DNA damage account for the different 
mechanisms of Cdc6 degradation.  
Cdc6 is substantially overproduced in a wide variety of cancer cell types. This 
overproduction results in a longer time needed to eliminate Cdc6 protein from cancer 
cells experiencing DNA damage than from normal cells, leaving a longer window of 
opportunity for these cells to assemble preRCs. The abundant Cdc6 that arises from 
near ubiquitous deregulation of the E2F-RB transcriptional program in cancers could 
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contribute to the observed genomic instability associated with transformation. We 
note that most cancer cells also have a disrupted p53 pathway that could blunt the 
APC-mediated mechanism of Cdc6 degradation. Thus Huwe1, which is also highly 
expressed in multiple tumor cell lines (Chen 2005, Yoon 2005), may represent the 
primary means of degrading Cdc6 in p53-null cells and may be particularly important 
in the response to chemotherapies that damage DNA. 
Huwe1-depletion in the absence of DNA damage did not result in overt 
rereplication (data not shown). If the purpose of Cdc6 degradation after DNA 
damage is to prevent rereplication, then it is likely that in order to observe significant 
rereplication in these short-term assays, not only would Cdc6 degradation need to be 
blocked, and perhaps Cdt1 degradation, but Cdk activity would need to be 
maintained in order to permit origin firing. We suggest however that over the course 
of many cell cycles the degradation of both Cdc6 and Cdt1 when cells encounter 
DNA damage contributes to maintaining strict regulation of preRC assembly or to 
promoting appropriate checkpoint and apoptotic responses. Consistent with this 
model, modest overproduction of Cdt1 has minimal effects on the growth properties 
or genome stability in cultured mouse cells, but those cells have a higher propensity 
for tumorigenesis in vivo [82]. We predict that stabilization of Cdc6 would have a 
similar phenotype, particularly in sensitized backgrounds or in cells subjected to 
repeated rounds of sub-lethal DNA damage. 
Although most of the other known targets of Huwe1 (p53, Mcl-1, and c-myc) 
are specific to metazoan species, Huwe1-dependent regulation of Cdc6 may be 
ubiquitous in eukaryotes, because both human and yeast cells rely on this conserved 
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enzyme for Cdc6 degradation. Cdc6 is certainly not the only target of Huwe1; Huwe1 
is a very large protein with multiple protein–protein interaction domains for binding 
other proteins [188, 192-194]. We propose the following model to accommodate 
what is currently understood concerning the regulation of human Cdc6 after DNA 
damage in the context of other recently identified Huwe1 substrates (illustrated in 
Figure 2.9B): During normal cell growth, Huwe1 ubiquitinates p53 to induce p53 
degradation [194] and ubiquitinates and activates c-myc [193]. Huwe1 ubiquitinates 
the anti-apoptotic Mcl-1 protein but its access to Mcl-1 is not obvious until cells are 
exposed to DNA damage ([188], and Zhong, unpublished observations). Hence, 
under normal growth conditions cells have active c-myc transcription, low p53, high 
Mcl-1, and cell cycle–regulated Cdc6 levels that are controlled by a combination of 
E2F-dependent transcription and APC-mediated degradation, and this combination 
supports robust proliferation (Figure 2.9B, left). In response to DNA damage Huwe1 
ubiquitinates Cdc6 and Mcl-1 to induce their degradation, but no longer ubiquitinates 
p53, resulting in low Cdc6 and Mcl-1 with stabilized p53, thus promoting cell cycle 
arrest, apoptosis, and inhibition of new preRC assembly (Figure 2.9B, right). 
Given the role of Huwe1 in the regulation of Cdc6, p53, c-myc, and Mcl-1, one 
might speculate that Huwe1 activity is regulated by DNA damage signals. 
Nevertheless we do not detect changes in Huwe1 protein levels after DNA damage 
(Figures 2.6D, 2.7, A, B, D, and 2.8 A,B,C) or during cell cycle progression (data not 
shown).  This study prompts significant questions regarding the intracellular context 
of the Huwe1-Cdc6 interaction and the upstream regulators of Huwe1 and/or Cdc6 
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during a DNA damage response. The regulation of Cdc6 by Huwe1 is likely to be 
complex, and its elucidation is an important future goal. 
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Figure 2.1. Cdc6 degradation after DNA damage depends on its 
abundance but not cell cycle phase. (A). Asynchronous HeLa cells were 
treated with 1 mM MMS lanes 2 and 5), with 30 J/m2 UV light (lanes 3 and 6) 
and with 20 µM MG132 (lanes 4–6), or left untreated (lane 1) as indicated. 
Cells were harvested 3 h after treatment, and endogenous Cdc6 and tubulin 
levels were determined by immunoblotting. (B). Cells were UV irradiated as in 
A, and endogenous Cdc6 and tubulin were monitored in whole cell extracts of 
60,000 HeLa or 120,000 NHF-hTert cells (normal human fibroblasts 
immortalized with telomerase) by immunoblotting. Both dark and light 
exposures of the Cdc6 signal are shown. (C). Asynchronous U-2OS cells were 
transduced with control virus or recombinant adenovirus producing Myc5-Cdc6 
at a relative MOI of 3 (lanes 1–4) or 9 (lanes 5–8). 24 h after infection cells 
were treated with 1 mM MMS for 3 h. Endogenous and ectopic Cdc6, Cdt1, 
and tubulin were detected by immunoblotting. (D). HCT116 cells were 
transduced with control virus or Myc5-Cdc6 producing virus at a relative MOI of 
25, then transfected with control siRNA or siRNA targeting geminin. 24 h after 
transfection, cells were synchronized in G2/M with 100 ng/ml nocodazole for 
20 h. Arrested cells were collected and analyzed by immunoblotting for 
phosphorylated Chk2, phosphorylated p53, ectopic Cdc6, or endogenous 
geminin and tubulin (left) and by flow cytometry for cells with greater than 4C 
DNA content. 
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Figure 2.2. The DNA damage-induced degradation of Cdc6 is independent of cell 
cycle phase. U-2OS cells were synchronized at G2/M by treatment with 2 mM
thymidine for 24 h followed 100 ng/ml nocodazole for 16 h. They were then collected by 
“mitotic shake-off” (lane 1) and replated. Cells were harvested at 3, 6, 9, 12, 15, and 18 
h after release. One duplicate of each sample was treated with 1 mM MMS for 3 h 
before harvest. (A). Cells were fixed and stained with propidium iodide and processed 
by flow cytometric analysis.  (B).  Endogenous Cdc6 and tubulin were evaluated by 
immunoblotting.
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Figure 2.3. Cdc6 degradation after DNA damage is independent of Cdk phosphorylation, 
APCCdh1, and p53 status. (A). HeLa cells were infected with recombinant adenovirus 
producing GFP (control), myc-tagged Cdc6 (WT), or myc-tagged Cdc6 in which S54, S74, and 
S104 have been altered to aspartic acid. Viral doses were used that result in levels of ectopic 
Cdc6 that are lower than endogenous Cdc6 (the top panel is a longer exposure of the Cdc6 
immunoblot than the middle panel). Cells were treated for 19 h with 3 mM thymidine to arrest in 
S phase before UV irradiation. Whole cell lysates were prepared 3 h after UV treatment, and 
both endogenous and ectopic Cdc6 and endogenous tubulin were detected by immunoblotting. 
(B). Asynchronous HeLa cells were treated with Cdh1 siRNA (lanes 3 and 4) or control siRNA 
(lanes 1 and 2) for 36 h. Three hours before harvest MMS was added to 1 mM (lanes 2 and 4). 
Endogenous Cdc6, Cdh1, cyclin B, and tubulin were analyzed by immunoblotting. (C). Normal 
human fibroblasts (immortalized with telomerase) or an isogenic derivative expressing a short 
hairpin RNA targeting p53 were treated with 1 mM MMS for 3 h and analyzed for endogenous 
Cdc6, p53, cyclin A, tubulin, and phosphorylated p53 (Ser 15) by immunoblotting. 
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Figure 2.4. Cdc6 degradation after DNA damage is independent of the Cul4DDB1 
ubiquitin ligase. (A).  HeLa cells were simultaneously treated with Cul4A and Cul4B 
siRNAs or control siRNA for 48 h followed by treatment with 1 mM MMS for 3 h. 
Endogenous Cul4A and Cdc6 were analyzed by immunoblotting. (B). Asynchronous 
HeLa cells were transfected with control or DDB1 siRNA for 48 h and then subjected to 
UV irradiation as in Figure 1A. Samples were collected at 0, 15, 45 min, and 3 h after 
irradiation, and endogenous Cdc6, Cdt1, and Ddb1 were analyzed by immunoblotting. 
(A nonspecific band is shown as a loading control.)
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Figure 2.5. Cdc6 interacts with a HECT family ubiquitin ligase Huwe1. 
(A). A schematic of the full-length Huwe1 protein (also known as Mule, 
Lasu1, ARF-BP1, UreB1, and HectH9) is provided: DUF908 and DUF913, 
conserved domains of unknown function; UBA, ubiquitin association domain; 
WWE motif, conserved putative protein interaction motif; BH3, Bcl-2 
homology region 3; HECT, homologous to E6-AP carboxy terminus 
(catalytic domain). (B). Gal4 DNA-binding domain fusions to the indicated 
Cdc6 sequences were expressed in a yeast reporter strain (PJ69a) with the 
C-terminal 240 residues of Huwe1 fused to the Gal4 transcriptional
activation domain. Interaction was scored relative to growth of the empty 
vector control on selective medium containing 30 mM 3-amino-1,2,4-triazole. 
(C) A schematic of independent isolates of two-hybrid fusions to Huwe1 
from Cdc6 interaction screens is shown. The amino acids included in each 
library clone are given; the longest clone was isolated twice. 
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Figure 2.6. The ubiquitin E3 ligase, Huwe1, binds Cdc6 and catalyzes its 
polyubiquitination. (A). The catalytic domain of Huwe1 (Huwe1C) was produced as a GST 
fusion in E. coli and incubated with a lysate of HeLa cells infected with adenovirus directing 
production of Cdc6 fused to five copies of the myc epitope tag (myc5-Cdc6). Ectopic Cdc6 
in portions of the input (5%) and in the fractions bound to glutathione beads was detected 
with anti-myc antibody. (B). GST and GST-Cdc6 were produced in insect cells from a 
baculoviral vector, isolated on glutathione beads, and incubated with a HeLa cell lysate. 
Endogenous Huwe1 in portions of the input (5%) and in the bound fractions was detected 
with anti-Huwe1 antibody. (C). Cdc6 purified as a GST fusion from insect cells and cleaved 
from GST with thrombin was incubated with glutathione beads in the presence of purified 
GST-Huwe1C. Cdc6 in the bound (lanes 2–4) and input (10%, lane 1) fractions was 
detected with anti-Cdc6 antibody; GST- Huwe1C was detected by Coomassie staining. (G).
Nuclear extracts of HeLa cells treated with MG132 for 3 h or with MG132 for 3 h after 30 J 
of UV irradiation, were digested with micrococcal nuclease to release Cdc6 from chromatin 
and then subjected to immunoprecipitation with normal rabbit serum (lanes 3 and 4) or anti-
Huwe1 antibody (lanes 5 and 6). Endogenous Cdc6 and Huwe1 in the input (1%, lanes 1 
and 2) and bound fractions (lanes 3–6) were detected by immunoblotting. (D). Purified 
GST-Cdc6 (100 ng) was incubated with ubiquitin, E1, and E2 enzymes plus the indicated 
concentrations of purified Huwe1 for 2 h as described in Materials and Methods. The 
reaction products were resolved by 6% SDS-PAGE and immunoblotted with anti-Cdc6 
antibody.
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Figure 2.7. Huwe1 is required for Cdc6 degradation after DNA damage. (A). 
Asynchronous HeLa cells were irradiated with UV and harvested at the indicated time 
points. The sample harvested 3 h after UV treatment was duplicated and treated with 
MG132 immediately after irradiation. Cells were fractionated into whole cell lysates and 
chromatin bound fractions and probed for endogenous Cdc6, Huwe1, and Orc2. (B).
Asynchronous HeLa cells were transfected with Huwe1 siRNA (lanes 4–6) or control siRNA 
(lanes 1–3) for 48 h. Cells were irradiated with UV as in Figure 1A, and endogenous Cdc6, 
Huwe1, and tubulin were detected by immunoblotting. (C). Left, HeLa cells treated with 
control siRNA or Huwe1 siRNA were fixed and stained with propidium iodide for analysis by 
flow cytometry 41 h after transfection. Right, cell numbers after transfection with control 
siRNA or Huwe1 siRNA were measured in duplicate cultures counted on 5 consecutive 
days. (D). HeLa cells were transfected with control siRNA (lanes 1–3) or Huwe1 siRNA 
(lanes 4–6) for 18 h followed by addition of thymidine for 18 h, for a total of 36 h in siRNA. 
Cells were treated with 1 mM MMS or 30 J/m2 UV 3 h before harvest in the continued 
presence of thymidine. Relative Cdc6 abundance was determined by densitometry and 
normalized to tubulin with the amount of Cdc6 in the first lane arbitrarily set to 1. 
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Figure 2.8. Huwe1 regulates Cdc6 stability following DNA damage. (A).  Left, 
HeLa cells were transfected with control siRNA or Huwe1 siRNA and blocked in S 
phase with thymidine. Cells were subjected to UV irradiation, and cycloheximide was 
immediately added to10 µg/ml in the continued presence of thymidine. Samples 
were collected at 0, 1, 2, and 4 h after UV treatment. Right, semilog plot of the initial 
rate of Cdc6 decay. The average half-life of Cdc6 in control-treated cells is 1.2 
(±0.18) h, and in Huwe1 siRNA-treated cells is 4.7 (±0.8) h. (B). HeLa cells were 
transfected with control siRNA or siRNA targeting Huwe1 for 30 h and incubated 
with 2 mM thymidine for an additional 18 h.  Cells were subjected to UV irradiation in 
the presence of cycloheximide (as in A).  Cells were harvested at the indicated times 
post-irradiation, and lysates were probed for endogenous Cdt1, and Huwe1; a non-
specific band serves as a loading control.  (C). HeLa cells were transfected with 
control siRNA or siRNA targeting Huwe1.   Duplicate samples were subjected to UV 
irradiation 3 h prior to harvest.  Cell lysates were probed for endogenous p53 and 
Huwe1; a non-specific band serves as a loading control.
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Figure 2.9. Conservation of Huwe1 regulation of Cdc6. (A). Yeast strains 
JCY200 WT and JCY201 tom1∆ in which the endogenous Cdc6 locus bears an in-
frame insertion of 13 myc epitopes at the 3′ end of the Cdc6 open reading frame 
(strains were constructed by K.S. Luce) were grown in YPD and treated with 0.05% 
(vol/vol) MMS. Time points were collected following the addition of MMS, and Cdc6 
was detected by immunoblotting with the anti-myc antibody; endogenous Mcm2 and 
phosphoglycerate kinase immunoblots are shown as controls. (B). Model: Cdc6 
degradation by APC and Huwe1 after DNA damage contributes to the balance 
between cell growth and apoptosis. Under normal cell growth conditions, Huwe1 
activates c-myc and induces p53 degradation. Cdc6 stability is primarily controlled 
by APC as cells transit mitosis. In response to DNA damage, p53 is stabilized, but 
Mcl-1 and Cdc6 are ubiquitinated and degraded. See text for discussion.
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Chapter 3 
 
 
 
 
Cdt1 and Cdc6 are destabilized by rereplication induced DNA damage 
 
 
 
 
 INTRODUCTION 
       One of the most critical events in the cell division cycle is complete and precise 
duplication of the genome.  In eukaryotic cells, origins of DNA replication acquire 
replication competence through the assembly of a prereplication complex (preRC) in the 
G1 phase of the cell cycle.  PreRCs are assembled by the sequential binding to origins of 
the origin recognition complex (ORC), Cdc6, Cdt1, and the minichromosome maintenance 
complex (MCM).  Origins harboring preRCs are licensed for replication but do not initiate 
DNA synthesis until S phase begins and the Cdc7 and Cdk2 kinases are activated [2, 3, 
90].  The large genomes of metazoan cells necessitate the utilization of thousands of 
origins, but each origin that initiates DNA synthesis must do so only once.  Failure to 
maintain this control has been linked to genome instability and oncogenesis [82, 199], but 
the cellular consequences of rereplication are not fully understood. 
Multiple regulatory mechanisms operate to ensure that origins that have “fired” do 
not fire again by blocking preRC assembly after the G1 to S phase transition.  Among the 
most important of these mechanisms are degradation of Cdt1 during S phase and 
inhibition of Cdt1 by the geminin protein.  Geminin depletion, overexpression of Cdt1, or 
overexpression of Cdc6 causes rereplication which ultimately triggers a DNA damage 
checkpoint [75, 78, 89, 154, 175, 176] and can promote tumorigenesis [82, 199].  
Rereplication induced by these manipulations, is however, uneven and incomplete, 
suggesting that one or more events restrain rereplication once it begins [75, 80, 172, 189, 
200, 201]. 
Previous investigators have noted that human or Drosophila cells depleted of 
geminin also become depleted of Cdt1 [186, 189], but the mechanism of that regulation 
has not been determined.  Moreover, the effects of rereplication on the Cdc6 protein have 
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not been explored.  We hypothesized that DNA damage caused by rereplication is 
responsible for the observed Cdt1 degradation and that a similar effect should result in 
degradation of Cdc6.  In this study we provide evidence that rereplication induced 
degradation of both Cdt1 and Cdc6 requires the same ubiquitin ligases that regulate Cdt1 
and Cdc6 in response to exogenous DNA damaging agents.  Moreover, Cdt1 
overexpression induces its own degradation by inducing rereplication associated DNA 
damage.  We further demonstrate that disrupting the degradation of either Cdt1 or Cdc6 
combined with geminin depletion exacerbates rereplication.  This study provides evidence 
for an evolutionarily conserved mechanism which destroys essential replication licensing 
factors once rereplication begins as an important means to minimize the extent of 
rereplication.
 
MATERIALS AND METHODS 
Growth of cells 
HCT116 cells were cultured in McCoy’s 5A medium (Cellgro, Mediatech) 
supplemented with 10% fetal bovine serum (Sigma), and 2 mM glutamine (Sigma).  NHF1-
hTert cells (NHF1) were grown in Dulbecco’s modified eagles medium (Gibco, Invitrogen) 
supplemented with 10% fetal bovine serum, and 2 mM glutamine.   
 
Small interfering RNA 
Cells were transfected at a final concentration of 100 nM siRNA using Dharmafect 
Reagent 1 (Dharmacon).  SiRNA sequences targeting geminin [186], DDB1 [202], Huwe1, 
or GFP (as a control) have been described [203].    
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Plasmids and viruses 
The HA2-Cdt1 adenovirus has been described {Braden, 2006 #37}1.  C-terminally 
tagged versions of Cdt1 were constructed by eliminating the Cdt1 stop codon in pENTR-
Cdt1 followed by clonase II recombination with pAD/CMV/V5-DEST according to the 
manufacturer’s recommendation (Invitrogen) 2.  Cdt1 was truncated after amino acid 321 
using a naturally-occurring NcoI site (Cdt1 ∆C); the PIPm mutation was generated in a 
PCR-based strategy. 
 
Cell cycle analysis 
Human cells were collected and processed for flow cytometric analysis by ethanol 
fixation and propidium iodide staining.  Nuclei were analyzed using the CyAn FACScan 
(DakoCytomation), and cell cycle distributions were plotted with Summit v4.3 software 
(DakoCytomation).  P values were evaluated using an unpaired t-test.   
  
Antibodies and immunoblots 
Anti-Cdt1 is described in Cook et al. [22]; anti-geminin (FL-209), anti-Cdc6 (180.2), 
and anti-HA (Y-11) were purchased from Santa Cruz Biotechnology.  Anti-DDB1 and Cul4 
antibody raised in rabbits against the peptide sequence MSAAKKYKPMDTTELHEN 
(Pocono Farms) were the gifts of Y. Xiong (University of North Carolina Chapel Hill.  
Antibodies to p53 phosphorylated at Ser15, Chk2 phosphorylated at Thr68, and Chk1 
phosphorylated at S317 were purchased from Cell Signaling Technologies.  Anti-V5 
                                             
1 HA-Cdt1 WT and HA-Cdt1 ∆C adenoviruses were constructed by K. Scott Luce 
2 C-terminally tagged versions of Cdt1and Cdt1 PIPm were constructed by Brandon D. Bunker and Jeanette 
Gowen Cook 
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antibody was purchased from Invitrogen.  Human tubulin antibody was purchased from 
Sigma, and anti-Huwe1 was a gift from S. Wing (McGill University). 
 
RESULTS 
Rereplication induces the degradation of Cdt1.   
We and others have previously observed that rereplication induced by RNAi-
mediated geminin depletion is incomplete.  To explore the mechanisms that restrain 
rereplication in these cells, we first manipulated the expression of both geminin and Cdt1 
in HCT116 colon carcinoma cells and analyzed the cells by flow cytometry to determine 
DNA content.  Depletion of geminin by siRNA transfection for 48 hours resulted in a 
population of cells with a heterogeneous DNA content greater than 4C which we defined 
as cells that had undergone rereplication (Figure 3.1A, left panels).  Rereplication can also 
be induced by overproduction of Cdt1 to levels that overwhelm the ability of geminin to 
inhibit Cdt1 activity [75].  Infecting cells with a recombinant adenovirus that directs 
moderate over-expression of an N-terminally HA-tagged Cdt1 induced rereplication after 
24 hours, although not as extensively as geminin siRNA transfection (Figure 3.1A, top right 
panel).  Combining Cdt1 expression with geminin depletion induced more extensive 
rereplication than either single treatment, as determined by the number of cells with DNA 
content greater than 4C (Figure 3.1A, bottom right panel).  Thus, geminin depletion and 
Cdt1 expression cooperate to induce rereplication. 
Recent evidence suggests that the forks derived from refiring origins collapse to 
generate double-strand breaks [59, 173] that can trigger activation of the DNA damage 
checkpoint.  As had been observed by others [80, 172, 204],  geminin-depleted cells 
acquired molecular markers associated with DNA damage, including phosphorylation of 
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both p53 and Chk2 (Figure 3.1B compare lanes 1 and 3).  Similarly, Cdt1 over-expression 
resulted in p53 phosphorylation (Figure 3.1B lane 2).  Seemingly paradoxically and similar 
to previous observations [186, 189], endogenous Cdt1 levels were quite low in geminin-
depleted cells despite the fact that Cdt1 is required for replication (Figure 3.1B, compare 
lanes 1 and 3).   
Cdt1 is most abundant in G1 cells, and geminin depletion results in fewer G1 cells 
(Fig. 3.1A).  To determine if the down-regulation of Cdt1 in geminin-depleted cells could be 
explained simply by this cell cycle effect, we treated cells with nocodazole after siRNA 
transfection to arrest them all in G2.  Geminin depleted G2 cells rereplicated as before 
(Figure 3.1C), but also had dramatically less Cdt1 than control G2 cells (Figure 3.1D).  A 
similar observation was made in G2-arrested cells by Ballabeni et al., and the loss of Cdt1 
was attributed to ubiquitin-mediated degradation [186].  Geminin binding to Cdt1 may 
physically block interaction with a Cdt1 ubiquitin ligase, or geminin may regulate Cdt1 
stability by some replication-independent mechanism. An alternative possibility we 
considered is that the DNA damage induced by rereplication results in Cdt1 degradation. 
Surprisingly, the ectopically expressed N-terminally tagged HA-Cdt1 protein was 
largely resistant to degradation in geminin-depleted cells, whereas the endogenous Cdt1 
was degraded (Figure 3.1B compare lanes 2 and 4).  Persistence of HA-Cdt1 may have 
contributed to the increased rereplication we observed when HA-Cdt1 was expressed in 
geminin-depleted cells.  The resistance of N-terminally tagged Cdt1 to degradation in 
geminin-depleted cells suggested that the Cdt1 N-terminus is important for regulating Cdt1 
stability in rereplicating cells.   In S phase, Cdt1 ubiquitination and destruction is mediated 
by two ubiquitin ligase complexes, SCFSkp2 and Cul4DDB1 [205]. Cul4DDB1 is also 
responsible for Cdt1 ubiquitination in response to DNA damage [164, 167].  SCFSkp2-
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mediated ubiquitination requires phosphorylation of human Cdt1 on T29 whereas DNA 
damage-induced ubiquitination of Cdt1 requires Cdt1 binding to PCNA (proliferating cell 
nuclear antigen), which also binds close to the Cdt1 N-terminus [149, 154, 155].  We 
hypothesized that N-terminally tagged Cdt1 was resistant to degradation in geminin-
depleted cells because one or both of these two ubiquitin ligases could not access Cdt1.  
To determine which mode of Cdt1 degradation was blocked by the HA tag, we monitored 
the stability of HA-Cdt1 expressed at near-endogenous levels as cells progressed through 
the cycle or in response to DNA damage.  Upon entry into S phase the HA-Cdt1 protein 
was degraded and then re-accumulated at the same cell cycle point as endogenous Cdt1 
(Figure 3.2A).  The fact that HA-Cdt1 is sensitive to cell cycle-dependent degradation but 
not degradation in geminin-depleted cells (Figure 3.1B) further demonstrates that the Cdt1 
degradation in geminin-depleted cells is not due to a passive cell cycle effect.  Unlike 
endogenous Cdt1, HA-Cdt1 was not degraded in response to ultraviolet irradiation (Figure 
3.2B); a similar observation had been made with N-terminally myc-tagged Cdt1 in UV-
treated cells [155]. These results suggest that the degradation of Cdt1 in geminin-depleted 
cells is accomplished by a mechanism similar to Cdt1 degradation in response to DNA 
damage, and are consistent with a model in which rereplication-induced DNA damage is 
the cause of Cdt1 degradation.  
 
The rereplication-induced degradation Cdt1 requires the PCNA binding site and 
Cul4DDB1.   
 
Through collaboration with Bob Duronio and his graduate student Hyun Lee they 
found that the Cdt1 ortholog double-parked (Cdt1Dup) is also degraded in response to 
geminin depletion through a mechanism that requires Cul4DDB1 (Hyun Lee data not 
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shown).  To determine if Cul4DDB1 is similarly required for degradation of human Cdt1 in 
rereplicating cells, we co-transfected HCT116 cells with siRNA targeting both geminin and 
the Cul4 adaptor DDB1.  As in Drosophila cells depleted of Cul4, depletion of DDB1 
prevented the Cdt1 degradation that occurred upon geminin depletion (Figure 3.3A, 
compare lanes 1 and 2 with lanes 3 and 4).  Since Cul4DDB1 is required for Cdt1 
degradation both after DNA damage and after geminin depletion, and since rereplication 
induces DNA damage, we hypothesized that Cdt1 degradation in geminin-depleted cells 
occurs by the same mechanism as in cells treated with exogenous DNA damaging agents 
such as ultraviolet irradiation (UV).  UV-induced degradation of Cdt1 requires an 
association between the Cdt1 “PIP” (PCNA interacting protein) motif and PCNA.  We 
therefore asked whether this association is also required for Cdt1 degradation in geminin-
depleted cells.  Conserved PIP motif residues at positions 3, 6, and 9 were altered to 
alanines (“PIPm-Cdt1”, Figure 3.3C); similar mutations have been demonstrated to be 
sufficient to disrupt PCNA binding and inhibit Cdt1 degradation after UV damage [154, 
155] (including the single mutation F9A in human Cdt1 [155].  A V5 epitope tag (or 
alternatively an RFP tag) was then inserted at the C-terminus of both normal and PIPm-
Cdt1.  To verify that the PIPm mutation blocks Cdt1 degradation in UV-treated cells, we 
expressed normal Cdt1 and PIPm-Cdt1 in HCT116 cells then treated with UV.   As 
expected, wild type Cdt1 is readily degraded after UV treatment, but PIPm-Cdt1 is not 
(Figure 3.2C). To test if an intact PIP motif is required for Cdt1 degradation in geminin-
depleted cells, WT Cdt1-V5 or PIPm-Cdt1-V5 were expressed from recombinant 
adenoviruses in HCT116 cells that had also been transfected with geminin siRNA.  Similar 
to Cdt1 degradation in UV-treated cells, the PCNA binding site was required for Cdt1 
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degradation in cells that had been induced to rereplicate by geminin depletion. (Figure 
3.3B, compare lanes 3 and 4 to lanes 5 and 6).   
The results described above are consistent with the model in which rereplication 
generates DNA damage which then stimulates the PCNA- and Cul4DDB1-dependent 
ubiquitination and degradation of Cdt1.  An alternative model is that geminin protects Cdt1 
from Cul4DDB1 binding through direct competition, and in the absence of geminin Cdt1 is 
more accessible to Cul4DDB1.  To test if the degradation of Cdt1 is a result of rereplication-
induced DNA damage or a consequence of competition between geminin and Cul4 for 
Cdt1 binding, we designed an experiment in which rereplication was induced by 
overproduction of the N-terminally tagged HA-Cdt1 protein instead of geminin siRNA 
transfection (as in Figure 3.1), and Cdt1 degradation was monitored by expression of low 
levels of the C-terminally tagged Cdt1-V5.  With increasing amounts of HA-Cdt1, WT Cdt1-
V5 was degraded (Figure 3.3D compare lanes 2-4), whereas PIPm-Cdt1-V5 was stable 
(Figure 3.3D compare lanes 7-9).  To distinguish whether the excess HA-Cdt1 induced 
Cdt1-V5 degradation by inducing rereplication or by sequestering geminin from Cdt1-V5, 
we overproduced a form of HA-Cdt1 truncated after amino acid 321 (“HA-Cdt1-∆C”).  The 
corresponding truncation of the Xenopus laevis Cdt1 fails to load the MCM complex or 
initiate replication but retains geminin binding [142].  We confirmed by co-
immunoprecipitation that this truncation of human Cdt1 binds geminin as well as full-length 
Cdt1 (Figure 3.4A) but fails to induce rereplication (Figure 3.4B).  HCT116 cells expressing 
high levels of HA-Cdt1-∆C failed to induce either the degradation of Cdt1-V5 or the 
phosphorylation of p53, though it accumulated to similar levels (Figure 3.3D lanes 5-6).  
These results indicate that it is the rereplication induced by geminin depletion that causes 
Cdt1 degradation. 
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 Degradation of Cdt1 limits the extent of rereplication. 
We hypothesized that the early stages of rereplication might generate sufficient 
DNA damage to trigger Cdt1 degradation, and that the loss of Cdt1 would then inhibit 
further origin re-licensing and rereplication.  If Cdt1 degradation is an important 
mechanism to restrain rereplication, then manipulations that interfere with Cdt1 
degradation are predicted to exacerbate rereplication.  To test that prediction, we infected 
geminin-depleted HCT116 cells with a moderate dose of the adenoviruses producing the 
stabilized PIPm-Cdt1-V5 (as in Figure 3.3B).  Quantification of the number of cells with 
greater than 4C DNA content revealed that PIPm-Cdt1-V5 expression promoted 
significantly more rereplication than did normal Cdt1 (“WT”).  Normal Cdt1 was degraded 
in geminin-depleted cells (Figure 3.3B) and thus had little additive effect on rereplication 
(Figure 3.5A and B).  Furthermore, a similar significant increase in rereplication was 
observed when endogenous Cdt1 was stabilized by co-depletion of DDB1 with geminin 
(Figure 3.5C and D).  While depletion of DDB1 induced a small amount of rereplication, 
and this rereplication has been shown to depend on Cdt1 [76], the number of cells that had 
rereplicated was highest in cells transfected with both geminin and DDB1 siRNA compared 
to cells transfected with either siRNA alone (Figure 3.5B).  Taken together, these findings 
suggest that rereplication is limited by Cdt1 degradation.  
 
 
Rereplication-induced degradation of Cdc6 requires the Huwe1 ubiquitin ligase.   
  
The preceding results suggested that the DNA damage caused by rereplication is 
sufficient to activate Cul4-dependent Cdt1 ubiquitination.  The only other component of the 
preRC that has been shown to be degraded in response to DNA damage is Cdc6 [138, 
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168, 203].  It thus seemed possible that the rereplication-induced DNA damage would also 
be sufficient to trigger Cdc6 degradation in geminin-depleted cells.  To test this idea, we 
monitored the levels of Cdc6 in several different cell lines transfected with geminin siRNA.  
Consistent with the presence of DNA damage as indicated by phosphorylation of p53 
(Figure 3.6A), Cdc6 was markedly down-regulated in geminin-depleted HCT116 cells.  We 
made similar observations in two other cell lines, HeLa and NHF1 [184].  NHF1 cells, like 
many other non-transformed cell lines, did not display an overt rereplication profile by flow 
cytometry (Figure 3.6B and Figure 3.7B) although geminin depletion was robust and p53 
was phosphorylated (Figure 3.6A, lanes 5 and 6). 
DNA damage-dependent ubiquitination of Cdc6 has been attributed to two ubiquitin 
ligases, depending on the cell type and source of DNA damage.  In p53-proficient cells 
treated with ionizing radiation, Cdc6 is down-regulated through ubiquitination by the Cdh1-
associated form of the anaphase promoting complex, APCCdh1 [138].  In response to other 
forms of DNA damage, Cdc6 is ubiquitinated by the Huwe1 enzyme irrespective of the p53 
status of the cells [203].  Since we observed Cdc6 degradation after geminin siRNA 
transfection in a variety of cell lines, including HeLa cells which have severely 
compromised p53 activity, we hypothesized that Huwe1 is required for Cdc6 degradation 
in geminin-depleted cells.  To test this hypothesis, we transfected NHF1 cells with siRNA 
targeting Huwe1 and geminin either singly or in combination, and then evaluated those 
cells for Cdc6 protein levels.  As before, geminin depletion induced a marked down-
regulation of Cdc6, but in cells co-transfected with Huwe1 siRNA, Cdc6 degradation was 
prevented (Figure 3.6C, compare lanes 2 and 4).  Strikingly, the combination of Huwe1 
and geminin depletion induced overt rereplication in NHF1 cells whereas neither treatment 
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alone was sufficient to cause DNA to accumulate to levels greater than 4C (Figure 3.6D, 
lane 4 and Figure 3.7B). 
 
Rereplication initiates prior to the degradation of Cdt1 and Cdc6. 
 How can a cell rereplicate when Cdt1 and Cdc6, two proteins required for 
replication initiation, have been degraded?  Presumably, the inappropriate re-licensing 
occurred before Cdc6 and Cdt1 were degraded.  To test that notion, we transfected 
HCT116 cells with siRNA targeting geminin and collected cells at various times after 
transfection.  Those cells were then evaluated for rereplication and the abundance of Cdt1 
and Cdc6.  Geminin was maximally depleted by 24 h after siRNA transfection, but 
significant degradation of Cdt1 and Cdc6 did not occur until 40 h after transfection (Figure 
3.8B).  Rereplication was detectable by flow cytometric analysis beginning at 24 h post-
transfection with the greatest number of cells harboring a DNA content of greater than 4C 
peaking at 48 h (Figure 3.8A).  The initial checkpoint response to rereplication-associated 
DNA damage has been linked to activation of Chk1 [201]}.  In these time courses, we 
observed that the activating phosphorylation of Chk1, as measured by phosphorylation at 
S317, coincided with the time when Cdt1 and Cdc6 had been degraded and the number of 
rereplicated cells had peaked and would increase no further (Figure 3.8, 40 and 48 h). At 
the latest time points, phospho-Chk1 had disappeared either due to signal quenching or to 
the induction of apoptosis which we observed as a population with sub-G1 DNA content 
(data not shown). These results indicate that once rereplication has begun Cdc6 and Cdt1 
are degraded, and the combination of their loss with the activation of a Chk1 response 
limits the extent of rereplication.  
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DISCUSSION 
In this report we provide evidence that DNA damage that results from rereplication 
induces the degradation of both Cdt1 and Cdc6.  Through collaboration with Bob Duronio 
and his graduate student Hyun Lee we show that this phenomenon is conserved in both 
human and Drosophila cells with respect to Cdt1 regulation, and perturbations that 
interfere with degradation exacerbate rereplication. Origin re-licensing and consequent 
rereplication can be induced acutely by transfection with geminin siRNA or with high levels 
of ectopically expressed Cdt1.  These events may also occur under more physiological 
circumstances should cells lose regulation of Cdt1 or geminin, as is the case for many 
tumor cells [77, 206].  The ability of Cdt1 to cause rereplication when it is overproduced 
combined with the rereplication-induced degradation of Cdt1 indicates that Cdt1 
overproducing cells are actively working to degrade Cdt1 once rereplication begins.  In 
other words, excess Cdt1 bears the seeds of its own destruction.  As a consequence, 
rereplication from inappropriately re-licensed origins prevents additional origin re-licensing 
because both Cdc6 and Cdt1 are absent (Figure 3.6A and 3.8C).   
The DNA damage that results from rereplication induces not only Cdt1 and Cdc6 
degradation, but also activation of the DNA damage checkpoint [75, 80, 172, 200, 201, 
204].  One of the principal outcomes of checkpoint activation is the inhibition of cyclin/Cdk 
activity.  The relationship of Cdk activity to origin activity is complex, as Cdks are not only 
required for origin firing but they also act to prevent new origin licensing after the G1/S 
transition by phosphorylating preRC components [3, 87, 89, 90, 163, 176, 189, 207].  
Recent studies have shown that components of the DNA damage checkpoint signaling 
pathway that blocks Cdk activity play an important role in restricting the extent of 
rereplication when geminin is depleted or Cdt1 is overproduced [200, 201]. Activation of 
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Chk1 is predicted to block origin firing by inducing Cdk inhibition.  The role of the DNA 
damage checkpoint in restricting rereplication and the degradation of Cdc6 and Cdt1 will 
be discussed in Chapter 4.  
Inactivation of Cdks in rereplicating cells as a consequence of DNA damage checkpoint 
signaling has the potential to promote even further origin licensing.  In order to prevent the 
re-licensing of origins during the period of low Cdk activity, Cdk independent mechanisms 
to block preRC assembly are required.  Degradation of Cdt1 in response to double-strand 
breaks induced by ionizing radiation does not require phosphorylation by Cdk2 [155, 205] 
or signaling through the ATM/ATR checkpoint pathway [167, 197].  In that regard, it is 
important to note that although Chk1 is phosphorylated as Cdt1 is degraded (Figure 3.8B), 
checkpoint activation does not itself stimulate Cdt1 degradation; these events are 
independent of one another.  Huwe1-mediated Cdc6 degradation is similarly unaffected by 
Cdk2 phosphorylation {Hall, 2007}, though the effects of the checkpoint signaling pathway 
on Huwe1 activity have yet to be determined.  Furthermore, we have previously 
demonstrated that the DNA damage-dependent degradation of Cdt1 and Cdc6 are 
independent of one another [203].  Thus, the degradation of Cdt1 and Cdc6 in rereplicating 
cells represent two mechanisms that block further origin licensing when Cdk activity is low, 
and these responses reinforce the checkpoint restraints on rereplication.   
Many labs have noted cell line-associated diversity in the effects of geminin 
depletion on the final cellular DNA content.  Components of the DNA damage checkpoint 
pathway are frequently targets for mutational inactivation or deregulation during 
carcinogenesis, particularly the p53 branch of the pathway.  It has been suggested that 
differences in the status of this checkpoint contribute to the propensity of cells to 
extensively rereplicate their DNA [75, 201].  We propose that efficient degradation of Cdt1 
86 
and Cdc6 to block licensing combined with robust DNA damage checkpoint activation to 
prevent origin firing provides an effective restriction of rereplication (Figure 3.8C).  The 
diversity of rereplication phenotypes associated with different cell lines is then a reflection 
of differences in the genetic alterations that impact both the checkpoint response and the 
efficiency of Cdt1 and Cdc6 degradation.  In that regard, one of the many differences 
between individual cancers may be the ability to induce Cdt1 and Cdc6 degradation to limit 
rereplication and the genome instability that it promotes. 
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Figure 3.1. Cdt1, but not N-terminally tagged Cdt1, is degraded in geminin 
depleted cells.  (A). HCT116 cells were transfected with geminin siRNA or a 
control sequence for 24 h.  Cells were then infected with recombinant adenovirus 
expressing HA-Cdt1 or control virus at a multiplicity of infection (MOI) of 200 for 
an additional 24 h. Cells were fixed, stained with propidium iodide, and analyzed 
for DNA content by flow cytometry.  The percentage of the cell population 
harboring DNA content greater than 4C is reported under the brackets for each 
plot.  (B). A portion of the cells from A were assayed by immunoblotting with the 
indicated antibodies.  Both ectopic and endogenous Cdt1 were detected with anti-
Cdt1 antibody; phosphorylation of Chk2 at T68 and p53 at S15 were detected 
with phosphospecific antibodies.  (C). HCT116 cells transfected with geminin 
siRNA for 24 h were treated with nocodazole for an additional 24 h to arrest them 
in prometaphase (G2/M).  (D). A portion of the cells from C were assayed by 
immunoblotting with the indicated antibodies.
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Figure 3.2.  HA-Cdt1 is resistant to UV-induced degradation, but not 
cell cycle-dependent degradation. (A). HCT116 cells were infected with 
recombinant adenovirus expressing HA-Cdt1 at an MOI of 200.  Cells were 
then treated with 100 ng/µl nocodazole (Sigma) for 18 h to arrest cells at 
G2/M.  Arrested cells were collected by “mitotic shake off”, re-plated in 
nocodazole free medium and collected at indicated times after release.  
Endogenous (lower band) and HA- (upper band) were assayed by 
immunoblotting with anti-Cdt1 antibody.  (B). HCT116 cells infected with 
control or HA-Cdt1 adenovirus at an MOI of 50 for 24 h.  Cells were treated 
with 20 J/m2 UV.  Cells were collected at indicated times post-irradiation 
and assayed by immunoblotting as in A. (C). HCT116 cells were 
transfected with plasmid encoding C-terminally RFP tagged Cdt1 
(pDEST40-Cdt1-RFP WT), pCdt1-RFP PIPm or p-RFP vectors using 
polyethylenimine (Sigma).  24 h after transfection cells were UV-irradiated 
and collected 30 minutes after irradiation. Endogenous and Cdt1-RFP were 
detected by immunoblotting with anti-Cdt1 antibody.
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Figure 3.3. Rereplication-induced Cdt1 degradation requires DDB1 and the 
PIP motif of Cdt1.  (A). HCT116 cells were transfected with siRNA targeting 
geminin or DDB1.  Cells were treated with DDB1 siRNA for 72 h and geminin 
siRNA for 48 h.  Proteins were detected by immunoblotting as in Figure 1.  (B).
HCT116 cells were infected adenovirus expressing Cdt1-V5 WT or Cdt1-V5 PIPm 
at an MOI of 40 4 h prior to transfection with siRNA targeting geminin or control 
sequence.  Cells were collected 32 h after transfection and assayed by 
immunoblotting. (C). A Schematic diagram of full length Cdt1 and derivatives: PIP, 
PCNA Interacting Protein motif, MCM loading region, geminin binding region.  (D).
HCT116 cells were infected with Cdt1-V5 WT, PIPm Cdt1-V5 or control adenovirus 
at a MOI of 40 and with WT HA-Cdt1 or ∆C HA-Cdt1 at an MOI of 100 (+) or 300 
(++) for 24 h followed by immunoblot analysis. 
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Figure 3.4. Cdt1∆C does not induce rereplication. (A). HCT116 cells 
were infected with control, HA-Cdt1 WT or HA-Cdt1∆C adenovirus at an 
MOI of 150.  24 h after infection cells were harvested and analyzed for 
ectopic Cdt1 with anti-HA antibody or for rereplication by flow cytometry. 
(B). HCT116 cells were infected as in A for 24 h.  Cell lysates were probed 
for ectopic Cdt1 with anti-HA (top panel) or were subjected to 
immunoprecipitation with anti-HA antibody as in Hall et al. and probed for 
endogenous geminin (bottom panel).
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Figure 3.5. Cdt1 degradation limits the extent of rereplication.
(A). HCT116 cells depleted of geminin and infected with the indicated 
adenoviruses exactly as in Figure 3.3B were evaluated for 
rereplication by flow cytometry as in Figure 3.1A.  The percentage of 
the total population harboring DNA content greater than 4C is 
reported. (B). Representative histograms.  (C). HCT116 cells 
depleted of DDB1 and geminin exactly as in Figure 3.3A were 
evaluated for rereplication by flow cytometry as in Figure 3.1A.  (D).
Representative histograms.
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Figure 3.6. Geminin depletion induces Huwe1-dependent 
Cdc6 degradation.  (A). HCT116, HeLa, and NHF1 cells were 
transfected with geminin siRNA for 48 h and evaluated by 
immunoblotting with the indicated antibodies.  In order to prevent 
premature mitosis, HeLa cells were treated with nocodazole for 24 
h prior to harvest.  (B). The percentage of cells from A with 
greater than 4C DNA content determined by flow cytometry as in 
Figure 1A.  (C). NHF1-tert cells were transfected with Huwe1 
siRNA for 24 h then transfected with geminin siRNA for an 
additional 48 h.  Cell lysates were probed with the indicated 
antibodies.  (D). The percentage of cells from C with greater than 
4C DNA content determined by flow cytometry as in Figure 1A.
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Figure 3.7. Geminin depletion induces rereplication in normal and caner 
cells.  (A). Representative histograms from Figure 3.6A and B. (B).
Representative histograms from Figure 3.6C and D.  
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Figure 3.8. Rereplication is limited by the degradation of Cdt1 and Cdc6 
(A). HCT116 cells were transfected with geminin siRNA, harvested at the 
indicated times following transfection and evaluated by flow cytometric analysis.  
The percentage of the population containing DNA content greater than 4C at the 
indicated time points from three independent experiments is plotted.  (B).
Immunoblot analysis of lysates from a representative experiment in A.  (C).
Model.  Rereplication induced by either geminin depletion (or the overproduction 
of Cdt1 or Cdc6) results in DNA damage.  The DNA damage triggers the 
ubiquitination of PCNA-bound Cdt1 by Cul4DDB1 and ubiquitination of Cdc6 by 
Huwe1 as well as Chk1 activation.  Degradation of Cdt1 and Cdc6 prevents 
further rounds of relicensing, and Chk1 activation inhibits origin firing, thus 
limiting the extent of rereplication.
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Chapter 4 
 
 
 
 
Future directions based on unpublished data from Chapters 1 and 2 
 
 
 
FURTHER ELUCIDATE THE MECHANISM OF CDC6 DEGRADATION AFTER 
DNA DAMAGE.  
 
Background 
 
The bulk of my work describes a pathway in which Cdc6 is targeted for 
degradation through the Huwe1 ubiquitin ligase in response to UV or MMS 
treatment.  One question that remains unanswered from this work is what is the 
mechanism that targets Cdc6 for degradation by the Huwe1 ubiquitin ligase during a 
DNA damage response?  Moreover, the signals that regulate the degradation of 
Cdc6 upstream of ubiquitination are poorly understood.  Understanding the signals 
that promote ubiquitination of Cdc6 by Huwe1 is vital to our understanding of how 
origin licensing and replication is restricted during DNA damage. 
 Continuation of my published work has provided evidence that following UV 
irradiation Cdc6 is released from the chromatin.  Figure 2.7A showed that following 
UV irradiation the chromatin bound Cdc6 is severely reduced, whereas little change 
has occurred in the overall abundance of Cdc6.   This experiment suggests that 
DNA damage triggers the release of Cdc6 from chromatin before the protein is 
degraded (Figure 4.1).   Determining how Cdc6 is released from chromatin will help 
describe the mechanism of Cdc6 degradation following DNA damage. 
 
Does the preRC protect Cdc6 from DNA damage-induced degradation? 
One explanation for the relocalization of Cdc6 following DNA damage is that 
ubiquitination of Cdc6 results in its release from chromatin.  Furthermore, Cdc6 
could be protected from ubiquitination by association with preRCs, and it is only after 
a DNA damage response when Cdt1 is degraded that Cdc6 becomes accessible to 
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be ubiquitinated by Huwe1 and released from chromatin (Figure 4.2A).  To test if 
Cdc6 ubiquitination is blocked by the interactions between Cdc6 and other preRC 
components HeLa cells were transfected with siRNA targeting Cdt1.  Depletion of 
Cdt1 would prevent MCM loading onto chromatin and therefore only ORC and Cdc6 
would be present at the origins, permitting access to Cdc6 by Huwe1.  The thought 
being, if Cdt1 and MCM restrict Huwe1 from accessing Cdc6, then by depleting Cdt1 
we would expect Cdc6 to become more unstable.  Interestingly, when Cdt1-depleted 
cells were treated with UV, I observed no changes in the kinetics of Cdc6 
degradation compared to the control cells (Figure 4.2B).  These data suggest ORC 
bound Cdc6 is not a better substrate for ubiquitination than Cdc6 contained within a 
preRC and therefore it is not the formation of the preRC that protects Cdc6 from 
DNA damage-induced ubiquitination.  This data further strengthens our hypothesis 
that Cdc6 is released from chromatin in response to DNA damage to be 
ubiquitinated and degraded.  The data collected so far suggests that the interaction 
between ORC and Cdc6 may be disrupted following DNA damage and the 
mechanisms that may inhibit the ORC-Cdc6 will now be discussed.  
 
Is soluble Cdc6 a better substrate for ubiquitination following DNA damage? 
 
To test the hypothesis that soluble (non-chromatin bound) Cdc6 is a better 
substrate for the DNA damage-induced ubiquitination I sought to measure the 
stability of soluble Cdc6 following DNA damage.  Asynchronous HeLa cells were 
transfected with siRNA targeting Orc2.  Depletion of any ORC subunit from cells 
completely disrupts ORC formation (reviewed in [3, 89, 90]), and any results that are 
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observed are specific to the failure to assembly ORC and not due to loss of Orc2.  
Cdc6 binding to chromatin requires ORC; therefore disruption of ORC should inhibit 
Cdc6 chromatin association (Figure 4.3A).  In response to depletion of Orc2, I found 
that both Cdc6 and Mcm2 were not loaded onto chromatin, suggesting the siRNA-
mediated knockdown was effective in preventing Cdc6 chromatin loading (Figure 
4.3B left panel).  Strikingly, when Orc2-depleted cells were treated with UV radiation 
I observed that Cdc6 became more unstable.  Within 20 minutes of UV radiation 
Cdc6 was dramatically reduced in the Orc2-depleted cells.  This degree of Cdc6 
degradation is far greater than what was observed within 3 h in the control cells 
(Figure 4.3B right panel).   
Failure to license origins due to depletion of Orc2 could have resulted in a G1 
arrest.  Cdc6 levels are naturally low during G1 as a result of APCCdh1 [126, 135].  
Cyclin A is not expressed in G1 (reviewed in [208]), therefore cyclin A expression 
was used as a marker for changes in cell cycle distribution due to Orc2-depletion.  
The equal expression of cyclin A in control and Orc2-depleted cells confirmed the 
decreased stability of Cdc6 was not an indirect consequence of any cell cycle 
changes due to depletion of Orc2.  The decreased abundance of Cdc6 in response 
to Orc2-depletion supports the hypothesis that the release of Cdc6 from chromatin is 
required for the degradation of Cdc6 following DNA damage and suggests that Cdc6 
is ubiquitinated by Huwe1 off chromatin.  The mechanism of Cdc6 chromatin release 
may be critical in the regulation of Cdc6 following DNA damage and scenarios that 
promote the release of Cdc6 from chromatin will be proposed in this chapter. 
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Interestingly, the degradation of Cdt1 is not affected in response to DNA 
damage, suggesting that Cdt1 chromatin association through ORC is not required 
for the DNA damage-induced degradation of Cdt1 (Figure 4.3B).  A study in 
Xenopus showed that only Cdt1 that is chromatin bound via an interaction with 
PCNA is ubiquitinated by Cul4DDB1 [154].  If Cdt1 degradation following DNA damage 
in human cells requires chromatin association, then Cdt1 binding to chromatin is 
independent of ORC and likely proceeds through PCNA.   
 
Does DNA damage result in a modification of Cdc6 promoting its release from 
chromatin? 
 
In response to DNA damage Cdc6 may become post-translationally modified 
resulting in the release from chromatin (Figure 4.4 A-C).  Cdc6 is a substrate of 
cyclin-dependent kinases; however it is unlikely that these kinases are responsible 
for the release of Cdc6 from chromatin during a DNA damage response for the 
following reasons: Cdks are normally inhibited as a result of activation of a DNA 
damage checkpoint (reviewed in [159] and Figure 1.8) and I have shown that the 
UV-induced degradation of Cdc6 is independent of the known Cdk phosphorylation 
sites on Cdc6 (Figure 2.3A).  A more attractive hypothesis is that Cdc6 is a substrate 
of the DNA damage checkpoint kinases ATR or Chk1, and it is the phosphorylation 
by these kinases that triggers the relocalization of Cdc6 (Figure 4.4 A-B).  I have 
preliminary data that suggests the degradation of Cdc6 may in part proceed through 
the ATR checkpoint pathway.  I have shown that the degradation of Cdc6 is impaired 
in UV-irradiated HeLa cells that have been treated with caffeine, an inhibitor of the 
ATR DNA damage checkpoint pathway (Figure 4.5).  In untreated cells Cdc6 is 
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almost undetectable 2 h following UV radiation, however considerably more Cdc6 
remains 2 h later in cells treated with 15 mM caffeine (Figure 4.5 compare lane 3 to 
6).  Based on this experiment I will propose future experiments to further elucidate a 
role of the ATR/Chk1 DNA damage response in regulation of Cdc6 degradation 
following DNA damage. 
There are many unanswered questions regarding the ATR/Chk1 pathway and 
its role in Cdc6 degradation.  Does activation of either ATR or Chk1 result in the 
phosphorylation and release of Cdc6 from the chromatin following DNA damage?  
To begin to address this question, I could treat mammalian cells with a 
pharmacological inhibitor to Chk1, UCN-01 or target Chk1 and/or ATR using siRNA. 
Chromatin fractionation experiments could be used to monitor Cdc6 localization in 
response to DNA damage when components of the DNA damage checkpoint have 
been inhibited.  If Cdc6 is a substrate of ATR or Chk1, then inhibition should 
interfere with Cdc6 being released from chromatin and inhibit Cdc6 degradation after 
DNA damage.   
It is possible that the modification events that occur on Cdc6 which results in 
its release from chromatin are independent of Chk1 or ATR.  If this is the case, an 
alternative approach may be to examine the post-translational modifications of Cdc6 
following UV-irradiation using mass spectroscopy.  We have rabbit polyclonal 
antibodies against Cdc6 that I have already been shown to be able to 
immunoprecipitate endogenous Cdc6 from whole cell lysates.  This approach would 
allow for the detection of the exact residue modified and the type of modification 
(phosphorylation, acetylation, etc.) that occurs during a DNA damage response.  
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Using this information we could then construct Cdc6 mutants that mimic both a 
constitutively modified and unmodified state.  These Cdc6 mutants would contain an 
epitope tag (Myc, HA) so that the mutants would be distinguishable from the 
endogenous protein.  These mutants would be expressed in mammalian cells and 
monitored for changes in chromatin binding and protein stability following DNA 
damage.  
 One anticipated modification would be the acetylation of Cdc6.  While there 
is no published evidence that Cdc6 is acetylated, Cdc6 is known to interact with the 
histone acetyltransferase Hbo1.  Hbo1 has been shown to interact with subunits of 
the ORC complex and the MCM helicase [209, 210].  Additionally, Hbo1 is a positive 
regulator of preRC assembly, although the mechanism is unclear.  When Hbo1 
expression was inhibited in mammalian cells there was a defect in chromatin loading 
of the MCM helicase, even though ORC and Cdc6 displayed normal chromatin 
binding [210].  Additionally, when Hbo1 was depleted from Xenopus egg extract 
MCM loading and replication was inhibited, however this phenotype was rescued 
through the addition of Cdt1.  These results suggest that Hbo1 activity is required for 
origin licensing and proper preRC formation through recruitment of the MCM 
complex to chromatin [210].  Furthermore, in unpublished data provided by Dr. Yue 
Xiong, several peptides of Cdc6 were isolated in a proteomics screen for proteins 
containing acetylated lysines.  Three potential acetylated lysines were identified in 
this screen, but only lysine residues 57 and 531 are conserved through metazoans.  
The potential acetylation of K57 is very intriguing since this residue lies within the 
Cdk phosphorylation region of Cdc6, a region that is known to regulate Cdc6 
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abundance and preRC formation.  Currently, Cdc6 mutants are being generated 
which contain mutations in the predicted acetylated lysine residues.  These lysines 
will be altered to arginine and glutamine to mimic the constitutively acetylated and 
un-acetylated forms of Cdc6 respectively.  These mutants will be assayed for their 
ability to bind ORC and chromatin under normal growth conditions and in response 
to DNA damage, as well as overall protein stability following DNA damage.  If the 
presence or absence of acetylation regulates Cdc6 chromatin binding or protein 
stability following DNA damage, then interfering with this regulation of Cdc6 could 
result in the inability to degrade Cdc6 in response to DNA damage.    
 
Does DNA damage disrupt the Cdc6-ORC interaction? 
It is possible that in response to DNA damage the interactions between Cdc6 
and components of the preRC become altered and loss of these interactions is what 
results in the release of Cdc6 from chromatin.  My preliminary data suggest that the 
Cdc6-ORC interaction may be disrupted following DNA damage (Figure 4.3B).  Cdc6 
binds directly to the ORC complex, however it is unknown which subunit(s) of ORC 
Cdc6 binds directly.  It is unlikely that the loss of the Cdc6-ORC interaction is due to 
the DNA damage-induced degradation of ORC, since no subunits of ORC have 
been shown to be unstable after DNA damage.  Recently, Orc3 and Orc6 were 
identified in a proteomics screen for substrates of the ATM and ATR DNA damage 
kinases following DNA damage [211].  One hypothesis is that the DNA damage-
induced phosphorylation of ORC induces a conformational change that releases 
Cdc6 from chromatin where it can be ubiquitinated by Huwe1 and degraded (Figure 
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4.4D).  To address these questions I can use siRNA molecules targeting ATM and 
ATR, in addition to deletion of ATR by Cre-lox mediated recombination using a 
conditional knockout HCT116 cell line that has been supplied to us by Dr. David 
Cortez at Vanderbilt University [57], to determine the role of ATR and ATM in 
regulating Cdc6 chromatin association and binding to ORC.  I expect that inhibition 
of the ATR or ATM DNA damage responses would prevent phosphorylation of Orc6 
and Orc3 thereby preserving the interaction between Cdc6 and ORC on chromatin 
and preventing the degradation of Cdc6. 
To further test if the phosphorylation of Orc3 and/or Orc6 affect Cdc6 
chromatin binding during a DNA damage response we can alter the predicted 
ATM/ATR phosphorylation sites for Orc3 (S208 and S516) and Orc6 (T229) to 
unphosphorylatable alanine or to aspartic acid to mimic the phosphorylated state 
[211].  These mutants would then be expressed in mammalian cells and assayed for 
changes in the ability to bind Cdc6 using co-immunoprecipitation experiments as 
well as effects on Cdc6 chromatin association.  As a control it is important to test if 
these mutations have disrupted the ability of Orc3 and Orc6 to bind DNA, thereby 
disassembling ORC.  If phosphorylation of Orc3 or Orc6 is the molecular signal 
responsible for the release of Cdc6 from chromatin than by expressing the mutant 
ORC subunits I would expect to observe persistent Cdc6 chromatin association after 
DNA damage. 
In addition to Orc3 and Orc6 several components of the MCM complex have 
also been identified as targets of ATM and ATR [57, 211].  Mcm2 and Mcm3 have 
been confirmed experimentally as ATM/ATR substrates [57], whereas Mcm6 and 
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Mcm7 are predicted substrates based on the presence of SQ/TQ motifs [211].  
However, I predict that these phosphorylations would have little effect on Cdc6 
chromatin stability because, upon entry into S phase the MCM helicase travels with 
the replication fork, and Cdc6 remains at the origin until mitosis and probably is not 
associated with the MCM helicase outside of G1.  In addition, through Cdt1 depletion 
studies I have shown that Cdc6 degradation following DNA damage is independent 
of MCM chromatin loading.  Even though, the DNA damage-induced 
phosphorylation of the MCM subunits may not be required for the release of 
chromatin bound Cdc6, these phosphorylations may be important in the disassembly 
of preRCs at replication origins that have not fired, thereby providing an important 
mechanism to safeguard the genome in response to damage. 
 
Potential pitfalls in targeting the ATR/ATM DNA damage checkpoint pathway. 
 
In the experiments that target components of the DNA damage response 
(ATM, ATR, Chk1, and Chk2) it may be important to inhibit multiple components due 
to overlapping pathways.  For example, evidence has shown that ATR is responsible 
for the phosphorylation of Mcm2 however; ATM can also carry out this 
phosphorylation when ATR is absent [57].  The ability of ATM to substitute for ATR 
suggests that there is a possibility that there may not be an effect on Cdc6 chromatin 
association by inhibiting a single kinase.  In addition, the redundancy of the 
pathways may make determining the order of events that lead to Cdc6 degradation 
more complicated.  For example, in response to inactivation of ATR if I detect 
activation of Chk1 and degradation of Cdc6, I would conclude that ATM can 
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compensate for loss of ATR, and that Chk1 activation is required for Cdc6 
degradation.  I would then inhibit Chk1 and test Cdc6 stability following DNA 
damage.  However, if inactivation of ATR still activates Chk1 after DNA, but Cdc6 is 
stabilized I would conclude that ATR is required for Cdc6 degradation and ATM 
activity cannot fill the role of ATR is regulating Cdc6 stability. This knowledge will be 
very important when determining the biological role of Cdc6 degradation after DNA 
damage. 
 
Determine the physiological significance of Cdc6 regulation following DNA 
damage. 
 
My work thus far has highlighted that dysregulation of preRC components are 
often associated with enhanced genome instability; therefore the next step would be 
to understand the physiological significance of the DNA damage-induced 
relocalization of Cdc6 from chromatin.  If release from chromatin is a requirement for 
Cdc6 degradation, then failure to release Cdc6 from chromatin, through expressing 
Cdc6 mutants, Orc3 or Orc6 phosphorylation mutants, or inhibition of the ATR-Chk1 
checkpoint response, could inhibit protein degradation.  Low Cdk activity exists 
during a DNA damage response, and failure to degrade Cdc6 could result in origin 
re-licensing and consequently rereplication (Figure 1.3).  To test if persistent Cdc6 
chromatin interaction promotes genome instability flow cytometric analysis and BrdU 
incorporation, a synthetic thymidine analog that gets incorporated into a cell's DNA 
during DNA replication,  would be used to measure active replication and detect 
cells with rereplicated DNA.  In addition, chromatin fractionation experiments would 
be used to monitor any reloading of other replication factors onto chromatin.  These 
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future experiments would provide much insight into the mechanism of Cdc6 
degradation and how they may relate to a canonical DNA damage checkpoint 
response. 
 
FURTHER INVESTIGATE THE SIGNALS REQUIRED FOR CDT1 DEGRADATION 
FOLLOWING DNA DAMAGE. 
  
Degradation of Cdt1 requires nucleotide excision repair. 
One signal for the degradation of Cdt1 in response to DNA damage is the 
loading of PCNA (proliferating cell nuclear antigen) onto DNA.  Cdt1 mutants that 
are defective in binding to PCNA display increased stability following DNA damage 
(Figure 3.2).  There are two instances during the cell cycle in which PCNA is loaded 
onto DNA; PCNA is loaded at replication forks during S phase and during repair of 
damaged DNA (reviewed in [157] and [158]).  Nucleotide excision repair (NER) is a 
major repair pathway involved in the removal of DNA lesions formed by chemicals or 
radiation.  The NER pathway is composed of six repair factors (XPA, RPA, XPC, 
TFIIH, XPG, and XPF-ERCC1) which facilitate recognition of the damage, excision 
of the damage, and repair synthesis of the damaged DNA (Figure 4.6).  It is during 
the new synthesis of DNA that PCNA is loaded onto the DNA (reviewed in [158]).  
Even though much is known about the repair of various lesions, no link between 
Cdt1 degradation and DNA repair has ever been made.   
Individuals harboring defects in excision repair are diagnosed with 
photosensitivity syndrome called xeroderma pigmentosum (XP), characterized by a 
very high incidence of light-induced skin cancer.  At the level of DNA, failure to 
recognize and excise the DNA lesion would also prevent the DNA damage-induced 
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loading of PCNA potentially impacting the degradation of Cdt1.  To determine if the 
loading of PCNA onto DNA was required for degradation of Cdt1 following DNA 
damage, I obtained an established XP cell line, in which a transversion in the XPA 
gene resulted in loss of XPA expression (XPA-deficient cells).  In addition, I also 
obtained a derivative on the same XPA-deficient cell line, in which these cells were 
transfected with the full length cDNA of the XPA gene to correct the abnormal 
phenotype (XPA-complemented; both XPA cell lines were generously provided by 
Dr. Aziz Sancar, University of North Carolina at Chapel Hill).   
The XPA-deficient (GM04312) and XPA-complemented (GM15876A) cell 
lines were treated with UV irradiation to induce the degradation of Cdt1.  In the XPA-
complemented cell line I observed near complete degradation of Cdt1 20 minutes 
after UV radiation (Figure 4.7 compare lanes 1 to 3).  Strikingly, Cdt1 was 
dramatically more stable in the XPA-deficient cells following DNA damage, when 
less than half of the Cdt1 was degraded within 20 minutes (Figure 4.7 compare 
lanes 1-3 to 4-6).  Presumably, the increased stability of Cdt1 was the result of the 
inability of the XPA-deficient cells to load PCNA [212]; which has not been confirmed 
in this experiment. The stabilization of Cdt1 in the XPA-deficient cells following DNA 
damage was an extremely interesting result, although the degradation of Cdt1 
following DNA damage requires an interaction with PCNA, only in Xenopus has the 
ubiquitination of Cdt1 been shown to occur on chromatin.  ORC would have 
remained chromatin bound in the XPA-deficient cells, and therefore if in human cells 
Cdt1 degradation after DNA damage requires Cdt1 chromatin association, then Cdt1 
is recruited to chromatin via PCNA not ORC.  These findings supports the models 
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generated from work in Xenopus that Cdt1 must be chromatin bound to be 
ubiquitinated by the Cu4DDB1 ubiquitin ligase.  
 The mechanism by which Cdt1 reaches the chromatin is unclear.  Does the 
DNA damage-induced loading of PCNA bring with it Cdt1, or does Cdt1 bind only to 
chromatin bound PCNA?  Additionally, can the reloading of Cdt1 onto chromatin 
after DNA damage be detected?  These scenarios could all be tested using the 
XPA-deficient and XPA-complemented cell lines.  Furthermore, it would be 
interesting to test if Cdt1 degradation through Cul4DDB1 induced by other signals is 
impaired in XPA-deficient cells.  The degradation of Cdt1 in rereplicated cells 
requires Cul4DDB1 and failure to degrade Cdt1 exacerbated rereplication (Figure 3.3 
and Figure 3.5).  Therefore, is the XPA-deficient cell line more susceptible to 
rereplication following geminin depletion and is Cdt1 more stable than in the XPA-
complemented cell line?  These proposed experiments would further define the 
mechanism of Cdt1 degradation through the Cul4DDB1 ubiquitin ligase.    
 
UNANSWERED REREPLICATION QUESTIONS  
The long term effects of expressing non-degradable forms of Cdt1 and Cdc6. 
 
My model suggests that the extent of rereplication is restricted through the 
degradation of Cdt1 and Cdc6 as a result of an active DNA damage response 
(Figure 3.6C).  However, even when Cdt1 and Cdc6 are stabilized rereplication is 
not complete, meaning I do not observe a complete reduplication of the entire 
genome (cells possessing a DNA content of 8C).  These results pose the question, 
are the abundance of Cdt1 and Cdc6 the primary regulator of rereplication, or is the 
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degradation of these proteins a secondary response due to the activation of a 
checkpoint response which is the primary regulator of rereplication?   Additionally, 
what are the long term physiological consequences of expressing a stable form of 
Cdt1 and Cdc6?  To address these questions stable mammalian cell lines 
expressing wild-type Cdt1 and Cdt1 PIPm would be generated.  The Cdt1 PIPm 
mutant cannot bind PCNA and I have shown that this mutant is also defective in the 
Cul4DDB1 catalyzed degradation pathway (Figure 3.2C and 3.3B).  These cell lines 
would be established in the HCT116 cell line and stable expression would be 
achieved through integration of a retrovirus encoding Cdt1.  Overexpression of Cdt1 
can induce rereplication, changes in ploidy, translocations, transversions, and other 
chromosomal rearrangements leading to malignant behavior [75, 79, 80, 82, 85, 
172, 213].  If degradation of Cdt1 is the mechanism to restrict rereplication, I would 
expect cells expressing Cdt1 PIPm to have a higher frequency of these 
abnormalities compared to wild-type Cdt1 containing cells.  Metaphase spread 
analysis, fluorescent in situ hybridization (FISH), and immunofluorescence will be 
used to detect changes in individual chromosome number and structure.  As a 
control it is important to determine that by expressing Cdt1 PIPm the normal S 
phase degradation of Cdt1 is unaffected.  Failure to degrade Cdt1 during S phase 
can induce rereplication, and if the S phase destruction of Cdt1 is affected any 
effects on genome stability could be contributed to the inability to degrade Cdt1 
during S phase.  
Another approach to examine the effects of expressing a non-degradable 
form of Cdt1 would be to develop a Cdt1 wild-type and PIPm transgenic mouse. 
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Previous work has shown that a Cdt1 transgenic mouse develops normally, however 
when this mouse line is crossed with a p53 null mouse 100% of the mice develop 
thymic lymphoblastic lymphomas, compared to 40% in the p53 null mice [85].  I 
speculate that a Cdt1 PIPm expressing mouse would be more susceptible to the 
development of tumors than the wild-type Cdt1 mouse due to the inability to degrade 
the excess Cdt1.   
Both Cdt1 and Cdc6 are required to license origins.  I have shown that Cdc6 
is also targeted for degradation in rereplicated cells (Figure 3.6 and 3.7B).  
Therefore, expressing stable forms of Cdt1 and Cdc6 could heighten the extent and 
consequences of rereplication.  It is possible that future studies examining the 
release of Cdc6 from chromatin following DNA damage may yield a mutant that is 
non-degradable in response to DNA damage.  However, my studies have shown 
that when Cdc6 is expressed at levels 5-10 fold above endogenous protein levels, 
that the ectopic protein is resistant to DNA damage-induced degradation (Figure 
2.1D).  Therefore, I can combine stable expression of Cdt1 PIPm and 
overexpression Cdc6 in HCT116 cells or transgenic mice to study chromosomal 
aberrations and predisposition for the onset of tumors.  Since both Cdt1 and Cdc6 
are required to license origins, I predict the most severe phenotypes with regard to 
increased genome abnormalities would occur in cells or mice when both Cdc6 and 
Cdt1 are unable to be degraded. 
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Is rereplication sequence specific? 
I observe that rereplication induced by overexpression of Cdc6 and Cdt1 or 
geminin depletion does not result in complete rereplication the entire genome.  This 
raises the question, is a specific sequence or region of DNA more susceptible to 
rereplication?  PCR-based analysis of the lamin B2 locus from geminin-depleted 
HCT116 cells suggests that early origins have a higher propensity to rereplicate 
[172].  However, FISH analysis of the lamin B2 and β-globin origins suggest that 
both early and late firing origins rereplicate when geminin has been depleted from 
HCT116 cells [80].  To further investigate whether rereplication favors early or late 
firing origins, microarrays would be used to test of changes in rereplication across 
the.  Furthermore, it could be determined if regions of DNA prone to rereplication 
correlate to regions of active gene transcription.  Since heterochromatin regions of 
DNA are tightly compacted potentially restricting access by factors required for 
replication, I speculate that rereplication would favor regions of euchromatin.  These 
experiments would help determine if rereplication occurs randomly or favors a 
specific DNA region or sequence. 
 
The role of the DNA damage checkpoint in restricting rereplication. 
Rereplication activates Chk1 and Chk2 leading to the degradation of Cdc25 
and subsequently the exclusion of cyclin B from the nucleus inducing a G2/M arrest.  
This arrest is required to prevent cells with rereplicated DNA from entering mitosis.  
Recent work has shown that the ATR/ATM pathway as well as the 
Mre11/Rad9/Nbs1 (MRN) complex becomes active in response to rereplication [200, 
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201].  The MRN complex senses and binds to double-strand breaks (DSBs), initiates 
repair of the DNA, and is required for activation of the ATM/ATR DNA damage 
checkpoint.  However, it is unknown what role this pathway has on the degradation 
of Cdt1 and Cdc6 in rereplicated cells.  My preliminary data suggest that this 
canonical DNA damage response may regulate Cdc6 stability in UV-irradiated cells.  
To test the involvement of the checkpoint in the degradation of Cdc6 and determine 
the effects on rereplication I would use methods previously described in this chapter 
to inhibit the DNA damage checkpoint response.  Since studies have shown that 
abrogation of the rereplication-induced G2 arrest results in untimely entry into 
mitosis and apoptosis I would combine inhibition of the checkpoint proteins with a 
nocodazole arrest to prevent entry into mitosis [80, 172, 200, 201].  If the DNA 
damage checkpoint controls Cdc6 degradation, abrogation of the checkpoint could 
lead to enhanced rereplication.  Even if these two pathways are independent of each 
other combining stabilization of Cdt1 and Cdc6 (through inhibition of Cul4DDB1 and 
Huwe1) along with inhibition of the checkpoint, I could still observe an increase in 
the percentage of cells with rereplicated DNA.  These experiments could determine 
if rereplication control relies on checkpoint activation or Cdt1 and Cdc6 degradation 
in addition to activation of the checkpoint. 
 
Loss of the checkpoint protein p53 enhances rereplication. 
A key transducer of the ATR/ATM checkpoint pathway is the tumor 
suppressor protein p53. p53 contributes to the inhibition of Cdks and inhibition of 
origin firing and cell cycle progression. The low Cdk activity not only inhibits cell 
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cycle progression, but also removes a major mechanism to prevent origin re-
licensing. It has been described that rereplication occurs in cells independent of their 
p53 status [172].  However, does the elimination of the Cdk-mediated inhibition of 
origin licensing promote more rereplication?  To examine whether p53 restricts the 
extent of rereplication, I obtained a p53 null HCT116 cell line (HCT116 p53-/-) from Dr. 
Bert Vogelstein (Howard Hughes Medical Institute, The Johns Hopkins University 
School of Medicine) to compare the extent of rereplication when geminin was 
depleted in cells not expressing p53.  Since published reports showed abrogation of 
the rereplication induced checkpoint resulted in entry into mitosis and cell death, 
cells were treated with nocodazole to prevent entry into mitosis and arrest cells at 
G2/M.  Surprisingly, I observed when geminin was depleted in the HCT116p53-/- cells 
they induced more rereplication compared to geminin-depleted cells expressing p53, 
suggesting p53 is required to restrict rereplication (Figure 4.8A compare 36.0% 
rereplication to 26.6% rereplication).  Even though, p53 appears to be required to 
restrict rereplication; p53 does not appear to be required for the rereplication 
induced degradation of Cdt1.  In both cell lines Cdt1 was degraded to near 
undetectable levels in response to geminin depletion (Figure 4.8B compare lanes 1 
to 2 and 3 to 4).  These results suggest that I could observe enhanced rereplication 
in geminin-depleted cells when Cdt1 is stabilized and the ATR-Chk1 checkpoint has 
been inhibited.  In addition, these findings support the hypothesis that there is more 
than one mechanism to restrict rereplication; activation of a checkpoint response 
and degradation of Cdt1 and Cdc6. 
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Potential pitfalls of the long-term rereplication studies. 
When studying the long-term effects of the inability to degrade Cdt1 and Cdc6 
the ideal approach is through manipulating Cdt1 and Cdc6, not through inhibiting the 
ubiquitin ligases, Cul4DDB1 and Huwe1.  Prolonged growth in the absence of DDB1 
itself has been shown to cause rereplication and genome instability [76].  
Furthermore, Huwe1 has many substrates that regulate cell proliferation; such p53, 
and myc, therefore indirect phenotypes could result due to the misregulation of other 
Huwe1 substrates. 
These proposed studies would help define the cell’s response to the re-firing 
of origins in order to restrict rereplication as well as providing a better understanding 
of how the preRC components Cdt1 and Cdc6 are regulated in response to cellular 
stress.   
 
CONCLUDING REMARKS 
 The work described in this dissertation has gathered new evidence on the 
regulation of Cdt1 and Cdc6 in response to both exogenous and endogenous 
(rereplication) forms of DNA damage.  From this work and the work of others it is 
quite clear that the regulation of Cdt1 and Cdc6 is complex, sometimes redundant, 
and by no means completely understood.  It is fascinating the similarities in the 
ubiquitination of Cdc6 and Cdt1.  The cell has evolved to acquire two mechanisms 
for the degradation of these two proteins; the SCFSkp2 and Cul4DDB1 ubiquitin ligases 
for Cdt1 and APCCdh1 and Huwe1 for Cdc6.  These two pathways probably evolved 
due to the catastrophic consequences of dysregulation of Cdt1 and Cdc6.  However, 
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equally interesting are the differences in the degradation of Cdc6 and Cdt1.  Cdt1 
degradation requires an association with PCNA and a presumed interaction with 
chromatin.  However it appears that Cdc6 degradation requires the relocalization 
from chromatin thereby providing further evidence that great lengths are taken to 
minimize the opportunities for improper origin licensing.   
 Successful completion of the outlined experiments in this chapter would 
further our understanding of the mechanisms controlling Cdc6 and Cdt1 degradation 
and what the consequences of those regulatory events are.  While there is still much 
to learn, the mechanisms leading to the degradation of Cdt1 are much better 
described than the degradation of Cdc6 following DNA damage.  For example the 
release of Cdc6 from chromatin and the role of the ATR-mediate checkpoint in 
response to DNA damage remain unanswered. 
 Finally, characterization of the mechanisms controlling Cdc6 degradation in 
response to DNA damage would enable us to apply this knowledge to cell culture 
models and mouse models to delineate the role these mechanisms have in 
maintaining genome stability over multiple cell divisions.  Cdc6 as well as the other 
components of the preRC have been shown to be upregulated in numerous forms of 
cancer and increasing our understanding of the regulation of these proteins and the 
consequences when these mechanisms fail could provide much need information on 
the molecular signals that promote tumorigenesis.   
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Figure 4.1. Cdc6 is released from chromatin following DNA damage.  Model.  
In response to DNA damage, Cdc6 is released from chromatin through an 
unclear mechanism enabling Huwe1 to interact with and ubiquitinate Cdc6 
targeting Cdc6 for degradation.. 
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Figure 4.2. The preRC does not protect Cdc6 from degradation. (A). Model. 
One hypothesis is that access to Cdc6 by Huwe1 is blocked  by the other 
components of the preRC, and it is the degradation of Cdt1 which occurs much 
faster than Cdc6 degradation that enables Huwe1 to ubiquitinate Cdc6 and 
trigger the release from chromatin. (B). Aysnchronous HeLa cells were 
transfected with siRNA targeting Cdt1 (5’-CCUACGUCAAGCUGGACAATT-3’) as 
previously described, treated with 20 J UV and harvested at the indicated times.  
Cdc6 stability in whole cell lysate was evaluated by immunoblotting. 
A.
B.
Cdc6 
tubulin 
Cdt1 
1 2 3 4 5 6 7 8 9 10
post-UV (hr) 0 0.5 01 12 0.5 2 33
control siRNA Cdt1 siRNA
Huwe1
ORC
origin
MCM
Cdc6 ORC
origin
MCMCdt1
ORC
origin
MCM
Cdc6
Huwe1
X
Cul4DDB1l 1
Cdc6
Ub
Ub
Ub
Ub
118 
Figure 4.3.  Non-chromatin bound Cdc6 is more unstable following DNA 
damage. (A). Model.  To release Cdc6 from chromatin cells were depleted of 
Orc2, then irradiated with UV to test the hypothesis that soluble Cdc6 is a better 
substrate for Huwe1-catalyzed ubiquitination. (B). Asynchronous HeLa cells were 
transfected with siRNA targeting Orc2 (5'-GAGCUAAACUGGAUCAGCAAACU 
UU -3' ) as previously described.  120 h after initial siRNA transfection cells were 
irradiated with 20 J/m2 UV and harvested at the indicated times.  (Left panel) 
Cdc6 and Mcm2 release from chromatin was confirmed by chromatin 
fractionation as previously described and (Right panel) Cdc6 abundance was 
measured in whole cell lysate by immunoblotting.
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Figure 4.4. Models for Cdc6 release from chromatin following DNA damage.  
(A). Cdc6 is phosphorylated by ATR which triggers its release from chromatin.  
(B). Chk1 phosphorylates Cdc6, promoting the disassociation from chromatin.  
(C). An unknown modification of Cdc6 in response to DNA damage triggers the 
release from chromatin.  (D). ATR phoshorylation of ORC results in a 
conformational change of ORC inhibiting the Cdc6-ORC interaction and releasing 
Cdc6 from chromatin.
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Figure 4.5. Caffeine inhibits Cdc6 degradation after DNA damage.
Thymidine-arrested HeLa cells were irradiated with UV in the presence (lanes 4-
6) or absence (lanes 1-3) of 15 mM caffeine, and harvested at the indicated times 
after irradiation.  Endogenous Cdc6 and a non-specific background band were 
detected by immunoblot analysis.
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Figure 4.6. Nucleotide excision repair.  Following DNA damage from UV 
irradiation the nucleotide excision repair (NER) pathway is activated.  XPA, 
RPA and XPC-XPD-XPB-TFIIH recognize and bind the site of damage.  
XPF and XPG contain endonuclease activity and excise the area around 
the damage.  Once the damage has been excised, RFC loads PCNA and 
DNA polymerase onto DNA to re-synthesize the DNA gap.
RPA
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Figure 4.7. XPA is required for Cdt1 degradation after DNA damage.  XPA-
complemented (GM15876) and XPA-deficient (GM04312) cell lines were 
obtained from Dr. Aziz Sancar (University of North Carolina-Chapel Hill) and 
maintained in minimum essential medium supplemented with 10% fetal bovine 
serum, 2 mM glutamine, and non-essential amino acids (Gibco, Inivitrogen).  
Cells were irradiated with 20 J/m2 UV and harvested at the indicated times.  
Endogenous Cdt1 and tubulin were evaluated by immunoblottting.
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Figure 4.8. p53 restricts the extent of rereplication.  HCT116 cells and 
HCT116     p53 -/- cells (gift from B. Vogelstein, HHMI, The Johns Hopkins 
University School of Medicine) were cultured in McCoy’s 5A medium (Cellgro, 
Mediatech) supplemented with 10% fetal bovine serum (Sigma), and 2 mM
glutamine (Sigma).  Cells were treated with control siRNA or siRNA targeting 
geminin for 24 h, then arrested at G2/M for an additional 24 h with 100 ng/µl 
nocodazole (Sigma).  (A). HCT116 cells were fixed and stained with propidium
iodide and processed by flow cytometric analysis.  (B). Endogenous Cdt1, 
geminin, p53 and tubulin were evaluated by immunoblotting.
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